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1. Introduction 
Systemic lupus erythematosus (SLE) is characterised by the production of antibodies 
to components of the cell nucleus in association with a diverse array of clinical 
manifestations. The basic pathological features of SLE are that of inflammation and 
blood vessel abnormalities, which include band or occlusive vasculopathy, vasculitis, 
and immune complex deposition. The best characterised organ pathology is in the 
kidney. By light and immunofluorescence microscopy, renal biopsies in patients with 
SLE display mesangial cell proliferation, inflammation, basement membrane 
abnormalities, and immune complex deposition, with immunoglobulins and 
complement components (Tumlin JA.2008). On electron microscopy, these deposits 
can be visualised in the mesangium and the subendothelial or subepithelial surface of 
the basement membrane. Current therapeutic regimen for lupus nephritis mainly 
comprised of medications which target abnormalities of immune regulation e.g. 
immunosuppressant B and T cell targeting drugs. Corticosteroids, antimalarial drugs 
and other therapies are being practiced along with immunosuppressants (Houssiau FA, 
Ginzler EM.2008).  
Even though we are yet to narrow down the exact aetiology of lupus pathogenesis, 
immunologists have enough idea about how the end stage organ damage happens? 
Researchers have been able to identify some of the inflammatory mediators which 
play important role in chronic tissue inflammation in lupus nephritis. With this 
information, we assume that reducing inflammatory mediators derived tissue 
destruction along with low exposure to immunosuppressants; can be an excellent 
approach to lupus nephritis treatment. In this study we evaluated the effectiveness of 
blocking CC-chemokine ligand 2 (CCL2) in a murine model of lupus nephritis using a 
novel tool to neutralize CCL2 in vivo. Before going in to details of the study, we will 
try to summarise known details of Lupus nephritis, about its histology, pathogenesis, 
role of different immune cell types (T cells, B cells), cytokines, chemokines and brief 
information about lupus therapy in this introductory segment. 
1.1 Lupus nephritis  
Lupus nephritis is one form of immune complex glomerulonephritis. The major 
immunological features of lupus are, loss of self tolerance to autoantigens, the 
presence of autoreactive B and T cells, with polyclonal activation of B-cells, the 
consequent production of autoantibodies by plasma cells, and the release of cytokines. 
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Anti-double stranded DNA antibodies (anti-dsDNA) are probably the most pathogenic 
type of antibody (Ab) produced. Other antibodies which bind to nucleosomes, laminin 
and collagen type IV also contribute to nephritis. The formation of immune 
complexes, the activation of the complement pathway and the defective clearance of 
immune complexes are also likely to play an important part in disease pathogenicity. 
1.1.1 Histology 
The International Society of Nephrology (ISN) and the World Health Organization 
(WHO) systems classify the various forms of lupus nephritis according to light, 
immunofluorescent and electron microscopic changes.  
As shown in Table 1, the WHO system of nomenclature identifies six different classes 
of lupus nephritis, with classes III and IV being the “proliferative” forms of the 
disease. By definition, patients with WHO class III have less than 50% of the volume 
of an individual glomerulus or less than 50% of the total number of Glomeruli with 
endocapillary proliferation. While many patients with severe class III may exhibit 
focal necrosis (karyorrhexis) or extracapillary proliferation (crescents), these findings 
are not required for staging a particular biopsy as class III or class IV. The overall 
prevalence of class III is 25% to 30%. In general, class III is associated with higher 
titers of anti-DNA antibodies, low complement levels, and active extra-renal 
manifestations of SLE. WHO class IV (diffuse proliferative) lupus nephritis shares 
many similarities with class III but generally demonstrates more extensive and 
aggressive histopathology. 
At the histology level, class IV is defined by the presence of endocapillary 
proliferation in greater than 50% of glomeruli. While not required for the diagnosis, 
patients with class IV lupus nephritis often demonstrate extensive crescents and 
karyorrhexis. At the clinical level, patients with class IV lupus nephritis frequently 
demonstrate severe extra-renal manifestations, including lupus cerebritis and lupus 
pneumonitis. 
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Table 1:  World Health Organization (WHO) nomenclature for classifying the various 
forms of lupus nephritis.  
 
Adopted from Tumlin JA 2008 
WHO Class Class I Class II Class III Class IV Class V Class VI 
Name Normal Mesangial 
Expansion 
Focal 
proliferative 
Diffuse 
proliferative 
Membranous Sclerosing 
Light 
microscopy 
Normal Mesangial 
proliferation 
<50% 
Glomeruli 
endocapillary 
proliferation 
>50% 
Glomeruli 
endocapillary 
proliferation 
Thickened 
capillary 
loops 
 
Interstitial 
Fibrosis 
 Normal IgG 
mesangial 
+/- 
Karyorrhexis 
Crescents 
+/- 
Karyorrhexis 
Crescents 
Absent 
proliferation/ 
crescents 
Glomerulo-
sclerosis 
Immuno-
fluorescent 
microscopy 
Immune 
complex 
deposits 
IgG/IgM 
mesangial 
staining 
IgG-IgM to 
full house 
IgG-IgM to 
full house 
IgG 
mesangial 
Subepithelial 
IgG/IgM 
mesangial 
Electron 
microscopy 
Immune 
complex 
deposits 
Mesangial 
dense 
deposits 
Mesangial 
subendothelial 
deposits 
Mesangial 
subendothelial 
subepithelial 
 
Mesangial 
Subepithelial 
Variable 
 
Membranous lupus nephritis (WHO class V) is present in between 10% to 20% of 
renal biopsies and is characterized by thickened capillary loops and mesangial 
expansion, but without significant crescent formation or endocapillary proliferation. 
However, the histopathology of class V is more diffuse than other forms of lupus 
nephritis and can be subdivided into three other forms. Patients with class Vb exhibit 
membranous features in conjunction with mesangial proliferation, while class Vc and 
Vd demonstrate focal or diffuse endocapillary proliferation. 
1.1.2 Pathogenesis of lupus nephritis  
Search of the precise immunopathogenesis of lupus nephritis has remained a challenge 
to many research groups all around the globe. This has led us to lots of conceptual 
theories which are published in recent times. Progression to lupus nephritis in SLE is 
thought to be dependent on the loss of self-tolerance and the formation of 
autoantibodies that deposit in the kidney to induce nephritis. Mechanistic studies in 
human and several murine models of SLE have shown that a variety of predisposing 
factors in the host must be present for these events to result in renal pathology.  
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Figure 1: Pathogenesis of systemic lupus erythematosus. (Adopted from Mok CC, Lau CS 
  2003) 
 
1.1.2.1 Predisposing factors associated with lupus nephritis 
Genetical factors 
Genetic susceptibility to lupus is inherited as a complex trait and studies have 
suggested that several genes could be important. Genes that contribute to the 
pathogenesis of systemic lupus are classified as follows: 1) Genes that cause break in 
tolerance for the self-antigens. 2) Genes that lead to immune dysregulation (loss of 
control of regulatory lymphocytes over the autoreactive lymphocytes). It is also 
suggested that multiple mutations, inherited or somatic, may be needed before a self-
reactive clone B and T lymphocytes bypasses sequential tolerance check points 
resulting in emergence of autoimmune disease (Goodnow.2007). 
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Hormonal factors 
SLE is a disease affecting women of childbearing age and there have been many 
anecdotal reports of exogenous oestrogens exacerbating lupus or increasing the risk of 
developing this disorder. Oral contraceptive use in the Nurses Health Study (Sanchez-
Guerrero J.1997) was associated with a slightly increased risk of disease with a relative 
risk for users versus never users of 1·9. Sex hormones are shown to affect T cells and 
B cells. Oestrogen has multiple effects of immune system. Oestrogen upregulates Bcl2, 
thus blocking tolerance induction of naive B cells (Bynoe MS. et al.2000). Either an 
increase in oestrogen or prolactin can break tolerance of high-affinity DNA-reactive B 
cells. Oestrogen, in this model, promotes the survival and activation of the T-
independent marginal zone B-cell subset (Grimaldi CM. 2006a). Thus, oestrogen may 
facilitate the maturation of pathogenic naive autoreactive B cells, whereas hampering a 
potentially protective autoreactive B-cell repertoire (Grimaldi CM. et al.2006b). In 
SLE T cells oestrogen increases expression of CD40L (Rider V. et al.2000). Oestrogen 
can activate dendritic cells (Hughes GC., Clark EA.2007). Prolactin has some effects 
that mirror oestrogen in the immune system and other effects that oppose it. For 
example, an increase in oestrogen or prolactin can break tolerance of high-affinity 
DNA-reactive B cells (Grimaldi CM.2006a). In murine SLE models, 
hyperprolactinemic mice have elevated albuminuria, regardless of oestrogen levels 
(Elbourne KB. et al.1998). 
Environmental factors 
Ultraviolet (UV), UV-A and UV-B, light has been classified as the classic 
environmental precipitant of SLE. Drugs like minocycline, and anti-TNF biologics, 
can lead to drug-induced lupus erythematosus (DILE). Sulfonamide antibiotics can 
induce idiopathic SLE. Subacute cutaneous lupus erythematosus (SCLE) is associated 
with thiazides, calcium channel blockers and angiotensin-converting enzyme 
inhibitors. Epstein-Barr viral infection has been strongly associated with SLE, in both 
children and adults in multicase SLE families. Amongst the other factors which are 
also associated with SLE are toxic exposures to silica and mercury (Mok et al.2003). 
We just had a brief overview of various predisposing factors of lupus nephritis, but 
what triggers the immune dysregulation? We know that SLE T cells and B cells lose 
the tolerance for self antigen, but what is the source of these self antigens? To 
understand this theory we will review the phenomena of apoptosis in the next section. 
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1.1.2.2 Apoptosis 
Cell death is the most likely phenomenon to supply autoantigens. There are two main 
forms of cell death, namely apoptosis and necrosis. Whether cells die through 
apoptosis or necrosis is determined by the initial stimulus and the microenvironment. 
Apoptosis is an active, programmed and regulated cellular process which appears 
under both physiological and pathological conditions in all tissues. In states of high-
rate tissue turnover like embryogenesis and development, apoptosis plays a critical 
role in the maintenance of a balance between old and new cells. Morphological and 
biochemical changes of dying cells are extremely important for their clearance from 
tissues by the scavenger system. If these cells are not cleared on time, they lose their 
membrane integrity and become secondarily necrotic; thereby releasing high amounts 
of modified nuclear and cytoplasmic material. Apoptosis is a tightly regulated process 
of programmed cell death that regulates the late phase of immune responses. 
Disordered regulation of both apoptosis and the clearance of apoptotic products have 
been implicated in the pathogenesis of SLE and lupus nephritis (Kamradt et al.2001). 
Under normal immune circumstances, activity against self antigens is prevented by 
several mechanisms, including the Apo-1/Fas pathway of apoptosis, which was shown 
to be involved in the process of immune tolerance by deletion of unwanted 
autoreactive T cells and B cells (Nagata S., Golstein P.1995). Defective Fas function 
therefore has the potential to lead to accumulation of lymphocytes, particularly 
autoreactive lymphocytes. This is the basic mechanism by which MRLlpr/lpr mice 
develop autoimmune syndrome.  
Cell death by necrosis, on the other hand, occurs when external factors strike cells. A 
violent interruption of their vital functions and finally a disruption of the plasma 
membrane are the consequences. This phenomenon is often triggered by an infectious 
agent, heat, ischaemia, low ATP levels or a mechanical injury (Rahman A., Isenberg 
DA.2008). No matter if cells die through apoptosis or necrosis, they must quickly be 
eliminated from tissues in order to prevent further damage. Early apoptotic cells are 
cleared by phagocytosis without eliciting either inflammation or immune response. 
Necrotic cells induce inflammation and favour the initiation of immune responses 
(Green DR. et al. 2009). There is growing evidence for a clearance deficiency of early 
apoptotic cells in mouse models of SLE (Taylor PR. et al.2000, Licht R. et al.2004) 
and in humans (Herrmann et al. 1998, Baumann et al. 2002). In later stage of 
apoptosis, apoptotic cells are called as secondary necrotic cells. Secondary necrotic 
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cells can release DNA-containing nucleosomes together with dangerous inflammatory 
signals towards immune system cells (Rovere P. et al.2000). It has been shown that 
the high mobility group B1 (HMGB1) protein, which is attached to the chromatin of 
apoptotic cells, remains immobilized even under conditions of secondary necrosis, 
while in the case of primary necrotic cells it is released and acts as an inflammatory 
cytokine (Voll RE. et al.2008). In clinical observations human SLE subjects had 
increased levels of circulating apoptotic mononuclear cells and dermal keratinocytes. 
The SLE patients had greater levels of circulating products of apoptosis such as 
nucleosomes than the controls. Autoantibodies associated with SLE reacted against the 
granzyme-cleaved nuclear products presented in the surface membrane blebs of 
apoptotic cells. While increased rates of apoptosis and/or reduced clearance of 
neoantigens created by apoptosis might lead to increased autoantibody production, one 
mechanism by which direct renal damage might occur in lupus nephritis is by 
increased rates of apoptosis among resident cells. In a murine model of lupus 
nephritis, caspase inhibitor therapy reduced glomerular injury (Seery JP. et al.2001). 
These combined observations suggest that disordered regulation of apoptosis might 
contribute to the lupus nephritis phenotype at different stages in the progression of the 
disease. 
So we know that apoptotic bodies are one of the major sources of auto antigens. If we 
look at the physiology of cell, every cell undergoes apoptosis at one point of time in its 
life cycle. But at the same time in a healthy individual clearing mechanisms are 
appropriately placed to clear the debris. In addition to that healthy immune system is 
tolerant to self. But in SLE the immune system is deregulated and increased generation 
of autoreactive B and T cells takes place along with the reduction of regulatory T cells. 
The regulatory T cells lose its control on the expansion of T cells. Circulating 
autoantigens or immune-complexes which are non antigenic in healthy conditions, are 
recognised as danger signals which further lead to excessive activation of immune 
system in SLE. (Goodnow.2005, 2007; Marshak-Rothstein.2006, Mok et al.2003). In 
the next parts of the introduction we will try to have an overview of the T cells and B 
cells characteristics in lupus nephritis. 
1.1.2.3 Role of T cells  
Among the cells that participate in the initiation, progression and perpetration of the 
disease, T lymphocytes play a key role in all stages, also because the production of 
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pathogenic autoantibodies in SLE is a T-cell-dependent process (Datta SK, et al. 
1987). As major contributors to the disease, T cells in SLE display multiple 
abnormalities that reflect and partly explain some aspects of the complex disease 
process. 
T cells are functionally and phenotypically heterogeneous, and it has therefore been 
useful to classify and divide these cells into subgroups. One major distinction is based 
on the surface expression of CD8 on the T cells that have cytotoxic functions and CD4 
on the T cells that provide help to other cells (although each subset may also display 
the opposite function, under specific circumstances). Another important distinction for 
T cells is between naive (or virgin) T cells and memory T cells, in reference to the 
experience of the cell with the antigen after its migration from thymus. T cells can also 
be divided into regulatory T cells and effector T cells. Regulatory T cells are typically 
hyporesponsive to stimulation with antigen and suppress the activation or effector 
activities of other immune cells. Differently from regulatory T cells, effector T cells 
proliferate in response to antigen stimulation, secrete cytokines and help the function 
of cytotoxic T cells or B cells for the production of antibodies. Effector T cells are 
divided into T helper (Th)1, Th2 and Th17 cells, depending on the major cytokines 
that they produce. Th1 cells mainly make IL-2 and IFN-γ (which favour the 
elimination of pathogens), Th2 cells produce IL-4 and IL-13 (which associate with 
allergy and parasitic infection) and Th17 cells make the proinflammatory cytokine IL-
17. 
The CD8+ T cells in SLE are impaired, and activated CD4+ helper T cells produce 
elevated amounts of cytokines and help B cells to secrete autoantibodies that form 
immune complexes which can bind to and/or remain trapped in tissue, with subsequent 
inflammation and organ damage. Most of the disturbed T cell homeostasis in SLE 
seems to depend on aberrant mechanisms of peripheral control, and it is generally 
thought that central tolerance (that during thymic development allows the deletion of 
autoreactive T cells before they migrate to the periphery) may not be affected or can 
only partly influence T-cell autoimmunity in SLE (Wither J., Vukusic B.1998, 
Fatenejad et al.1998). On the contrary, several mechanisms of peripheral immune 
tolerance are abnormal in SLE T cells, including: a) resistance to the induction of 
anergy (Xu L. et al.2004), b) reduced apoptosis and impaired clonal deletion of 
autoreactive T cells ( Budagyan et al. 1998), c) increased spontaneous signalling and 
decreased threshold for the activation of T cells, and d) reduced number and/or 
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function of regulatory T cells (in addition to indirect factors such as an abnormal 
cytokine production that contribute to immune deviation). 
SLE T cells display spontaneously increased activation associated with a reduced 
threshold of activation to self antigens, yet they are hyporesponsive to further 
antigenic stimulation (Murashima et al.1990, Dawisha et al.1994), furthermore they 
are resistant to apoptosis (Budagyan et al. 1998), show increased survival after 
activation, and have many altered intracellular signalling pathways. At the molecular 
level, T cell recepator (TCR) stimulation in lupus T cells associates with an increased 
signalling protein phosphorylation and a sustained increase in free intracellular Ca++ 
(Vassilopoulos et al.1995). Lupus T-cell deficiencies in signaling pathways include a 
decreased expression of the CD3 ζ chain, a decreased expression of protein kinase 
(PK)C, a reduced expression of the p65-RelA subunit of the transcription factor NF-
κB, a decreased activity of PKA, a decreased phosphatase activity of CD45 (Takeuchi 
et al.1997), a reduced levels of the intracellular signalling protein Lck in lipid rafts 
(Jury et al.2003) and a defective phosphorylation of Cbl-b, a factor that negatively 
regulates transmembrane signaling (Yi et al.2000). Other abnormalities include an 
increased binding of the transcriptional inhibitor cyclic AMP response element 
modifier (pCREM) to the IL-2 promoter (Tenbrock et al.2003). IL-2 abnormalities 
have a central relevance in the activity and function of T cells in SLE. IL-2 is a pivotal 
regulator of T-cell responses, and it is reduced in lupus mice and in some patients with 
SLE. Additional molecular mechanisms that could contribute to impaired T-cell 
functions in SLE include histone acetylation and methylation, as shown by the finding 
that treatment with histone deacetylase inhibitors can suppress murine lupus (Mishra 
et al.2003). 
1.1.2.4 Role of B cells 
The role of the B cell in the pathogenesis of immune mediated glomerulonephritis 
(GN) has traditionally been viewed as limited to that of antibody producer.  However, 
it is increasingly appreciated that B cells contribute to the pathogenesis of GNs in 
many other ways. They can function as potent antigen-presenting cells (APCs), and in 
this role, their ability to clonally expand makes them highly efficient activators of 
antigen-specific T cells. More recent evidence suggests that B cells also play a role in 
the production of lymphangiogenic factors; thus, the B cell may orchestrate the local 
expansion of lymphatics required to support a florid immune response. Furthermore, B 
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cells may regulate T cells and dendritic cells (DCs) through the production of 
cytokines or regulatory antibodies.  
Evidence for an antibody-independent role for B cells is suggested by animal models, 
that is, an MRLlpr/lpr lupus prone mouse with nonsecretory plasma cells developed 
evidence of autoimmune disease (Chan OT. et al.1999), yet B-cell-deficient MRLlpr/lpr 
mice did not (Shlomchik et al.1994). B cells producing autoantibodies in SLE have 
undergone extensive clonal expansion, suggesting that the antibodies are produced in 
response to chronic stimulation of B cells by antigen and costimulatory autoreactive 
CD4þ T cells—therefore suggesting an important role for the autoreactive T cell in 
addition to B lymphocytes. Another B-cell-related functions likely to be important in 
the pathogenesis of SLE is cytokine release, particularly proinflammatory IL-10, 
tumor necrosis factor (TNF)-, and IL-6, all of which are produced in high levels in 
SLE, and BlyS/BAFF (Blymphocyte stimulator/B-cell activating factor; a TNF-family 
cytokine that promotes B-cell maturation and survival and plasma cell differentiation) 
(Martin F., Chan AC. 2006). The role of the B lymphocyte as an APC is also likely to 
be essential in the development of autoimmunity. In experimental models of 
autoimmune arthritis, the APC function of B cells was essential for the development of 
disease, while the antibody-secreting function was not (O’Neill SK. et al.2005, Chan 
OT. et al.1999). Ultimately, activated B cells can aggregate into ectopic lymph node-
like structures containing plasmablasts, memory B cells, and plasma cells are observed 
in sites with chronic inflammation. 
1.1.2.5 Anti-DNA antibodies 
Antibodies to DNA were first described in 1957 (Holborow EJ. et al 1957). They 
constitute a subgroup of antinuclear antibodies that bind ssDNA, dsDNA, or both. 
They might be IgM antibodies or any of the subclasses of IgG antibodies. Anti-dsDNA 
antibodies are thought to play a crucial role in the pathogenesis of lupus nephritis 
(Hahn BH. 1998). In many patients with SLE, increased renal disease activity is 
associated with rising titres of anti-DNA antibodies. Antibodies to ssDNA and dsDNA 
are part of the normal repertoire of natural autoantibodies; most of these are low-
affinity IgM antibodies that react weakly with several self-antigens. However, these 
natural antibodies can undergo an isotype switch (from IgM to IgG) that increases 
their potential to be pathogenic. In addition, somatic mutations in the encoding 
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immunoglobulin genes might result in the production of high-affinity IgG antibodies 
to DNA. 
It is indisputable from histopathological analyses that immune aggregates are present 
at sites of injury in glomeruli. Whether these are derived from circulating immune 
complexes or from an in situ combination of antigen and antibody were once 
debatable. Although anti-dsDNA was once thought to cause glomerulonephritis by 
forming complexes with DNA that are passively trapped in the glomeruli, many 
investigators now believe that anti dsDNA antibodies are pathogenic to the kidney via 
direct (cross-reactivity) or indirect (via a nuclear antigen bridge) binding to glomerular 
structures. A series of studies by Chan et al (1995, 1997, and 2002) have shed light on 
the potential pathogenicity of anti-DNA binding to glomerular cells in lupus nephritis. 
Subsets of anti-DNA antibodies from patients with SLE were shown to bind to human 
mesangial cells and endothelial cells, and the cellular binding of these autoantibodies 
correlated with disease activity (Chan et al 1995, 1997, and 2002). In addition to cell 
binding, there is convincing evidence to show that anti-dsDNA penetrate into living 
cells. Administration of certain anti-dsDNA antibodies to nonautoimmune mice in 
vivo leads to cell penetration and intranuclear Ig deposits in the kidney and other 
organs (Madaio et al 1998). Apart from glomerular cells, renal tubular cells, 
hepatocytes, neuronal cells, fibroblasts and mononuclear cells are all susceptible to 
penetration by anti-dsDNA antibodies. One intracellular effect of anti-DNA antibodies 
is to enhance cell growth and proliferation, or conversely induce apoptosis. Madaio et 
al (1996) reported that nuclear localizing anti-DNA antibodies bind to DNAse I in 
living cells and inhibit the activity of this enzyme, making the cells more resistant to 
apoptosis. This observation might explain the finding of glomerular hypercellularity in 
mice injected with penetrating antibodies. In contrast, the cytopathic effects of anti-
dsDNA antibodies to induce cell death have been demonstrated by others. (Hsieh et al 
2001). Up-regulation of apoptosis by anti-DNA antibodies would be consistent with 
the observation that anti-DNA antibodies can enhance cleavage of DNA (Kubota et al 
1996). Apart from their effect on cell viability; anti-dsDNA antibodies might influence 
pro-inflammatory pathways upon their binding to cell membrane antigens and/or entry 
into the cell cytosol. 
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1.1.2.6 Nucleosomes 
Accumulating evidence suggests that autoantibody interactions occur with 
nucleosomes (complexes of DNA and histone-containing pairs of histone peptides 
around which dsDNA are wrapped twice. Antibodies reactive to nucleosomes have 
been detected both in SLE patients and in murine lupus models, even prior to the 
development of anti-dsDNA and antihistone antibodies (Monestier M.1997). These 
antibodies are immunoglobulin G in isotype, and bind to glomerular basement 
membrane via nuclesomes (Tax et al.1995). Generation of nuclesomes in vivo requires 
apoptosis (Casciola-Rosen L., Rosen A.1997). These nucleosomes and intracellular 
debris appear as blebs on apoptotic cell surfaces, and might incite T cell-driven 
stimulation of B cells. The injection of syngeneic apoptotic cells into normal mice has 
been shown to generate antinuclear antibodies and immune deposition in kidneys 
(Mevorach et al.1998). Data generated by transmission electron microscopy, immune 
electron microscopy (IEM), and co-localization IEM analyses using experimental 
antibodies specific for dsDNA, histones, transcription factors, or laminin identified 
exposed glomerular basement membrane-associated nucleosomes as target structures 
for nephritogenic autoantibodies in vivo ( Kalaaji M. et al.2006a, 2006b, 2007). 
Furthermore, terminal deoxynucleotidyl-transferase (TdT)-mediated dUTP nick end-
labeling (TUNEL) assay and activated caspase 3 staining demonstrated that murine 
lupus nephritis was linked to the accumulation of apoptotic cells in glomeruli and 
chromatin in glomerular capillary membranes and in the mesangial matrix (Kalaaji M. 
et al.2006b, 2007). These data suggest that apoptotic nucleosomes can be released, 
bound to glomerular membranes, but not cleared. In this situation, they may be 
targeted by pathogenic anti-nucleosome antibodies. It would be reasonable to assume 
that nucleosomes are one of the major autoantigens in lupus nephritis and might well 
be the primary inciting stimulus for the ‘antigen-driven’ IgG immune response. 
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Figure 2: A, a typical transmission electron microscopy observation in lupus nephritis is 
glomerular basement membrane (GBM)-associated EDSs. B, bound antibodies are stained 
with gold particles. C, the EDSs are shown as dark unique structures. In D, it is shown how 
nucleosomes bind glomerular capillary membranes or the mesangial matrix (GBM) where they 
are observed as EDSs (Mortensen et al 2008). 
 
 
1.1.2.7 Complement  
An intimate but paradoxical relationship exists between the complement system and 
SLE. Kidney is an important source of complement synthesis. Activation of 
complements by immune complexes through classical pathway is supposed to be the 
main mechanism of tissue injury. Wang et al. demonstrated decreased proteinuria and 
renal disease in NZB/NZW F1 mice, a mouse model of SLE, after treatment with a 
blocking anti-C5 antibody (Wang Y. et al.1996). The involvement of the complement 
system in SLE occurs in three steps, known as the ‘waste disposal hypothesis’. The 
first step is the failure to clear autoantigens i.e. defective waste disposal (Walport 
MJ.2001). This is the stage at which complement deficiency might have a pathogenic 
role. The second step is the uptake of autoantigen by immature dendritic cells in the 
presence of inflammatory cytokines, which causes these cells to mature into antigen-
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presenting cells, allowing the presentation of autoantigens to T cells. The third step is 
the pathogenesis of lupus nephritis provision of help by T cells to autoreactive B cells, 
which have taken up autoantigen by means of their immunoglobulin receptors. Such B 
cells mature into plasma cells that secrete autoantibodies. It is likely that in the 
majority of patients, SLE develops only in the presence of abnormalities in more than 
one of these steps. At the same time hereditary deficiencies in the complement 
components of the classical pathway increase the risk of lupus and lupus like disease. 
Deficiencies in C1, C2, C4 and CR1 predispose an individual to the development of 
SLE. C1q-deficient mice developed renal injury with vascular thrombosis, proteinuria 
and renal failure (Robson et al.2001).  Animal studies have produced conflicting data 
as to whether C3 confers protective or harmful effects (Einav S. et al.2002, Sekine H. 
et al.2001). At present, it is difficult to reconcile the potentially positive and negative 
impacts of complement in SLE. It is difficult to ascribe the role of complement in 
lupus as a bystander effect, especially when complement has several potent effector 
mechanisms to induce inflammation and tissue damage. 
1.1.2.8 Role of cytokines  
The role of TNF-α in lupus is controversial. This cytokine may be protective in 
patients with lupus, since giving TNF-α to lupus-prone NZB/W F1 mice delayed the 
development of lupus (Jacob CO., McDevitt HO.1988). The protective effect is 
specific to that mouse strain, and the mechanism is unknown. In some patients with 
rheumatoid arthritis who were treated with anti–TNF-α antibodies, anti–dsDNA 
antibodies developed (Charles PJ. et al.2000), and lupus erythematosus developed in a 
few of these patients (Mohan AK. et al.2002). Serum levels of IL-10 are consistently 
high in patients with lupus, and they correlate with the activity of the disease 
(Houssiau FA. et al.1995). IL-10 has a number of biologic effects, including 
stimulation of polyclonal populations of B lymphocytes. Blocking this cytokine could 
reduce the production of pathogenic autoantibodies.  
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Figure 3: Summary of abnormal cytokine profiles in skin, kidney and neurological systems. 
(Dean GS. et al.2000) 
 
Serum levels of interferon-α are also elevated in patients with active lupus (Rönnblom 
L., Alm GV.2003), and microarray studies showed that 13 genes regulated by 
interferon were up-regulated in peripheral-blood mononuclear cells from patients with 
lupus, as compared with similar cells from healthy controls (Baechler EC. et al.2003). 
In studies of lupus-prone NZB/W F1 mice, nephritis developed 15 to 20 weeks earlier 
in mice continuously exposed to interferon-α from a young age than in control mice 
not subject to this exposure (Mathian A. et al.2005). Anti-interferon drugs may be the 
next anticytokine agents to be developed as treatments for patients with lupus. 
The B-lymphocyte stimulator (BLyS) is a member of the TNF-ligand superfamily. It 
promotes the proliferation and survival of B lymphocytes. Circulating levels of BLyS 
are elevated in several other conditions, including rheumatoid arthritis and Sjögren’s 
syndrome, as well as in lupus. The overexpression of BLyS has been detected in both 
humans with lupus and lupus-prone mice (Cancro MP. et al.2009). 
IL-6 is yet another important cytokine which, among many other effects, induces the 
expression of acute phase proteins and also leads to increased antibody secretion by B-
lineage cells (Naka T. et al.2002). 
TGF could exert a bidirectional effect similar to the effects of the classical Th2 
cytokines, with less inflammation on the one hand, but more fibrosis on the other. 
TGF may also play a role for regulatory T cell action. Increased glomerular TGF 
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was found present and locally produced in samples of adults as well as children with 
lupus nephritis (Iwano M. et al.1994, Yamamoto T. et al.1996). In MRLlpr/lpr mice, 
where TGF is likewise over expressed, additional TGF was beneficial with regard 
to autoantibody formation, kidney disease and survival (Raz E. et al.1995), but its role 
in fibrosis has been suggested to be critical. 
1.1.2.9 Other inflammatory mediators of cell migration in chronic inflammation 
So far we have seen how the immunological reaction is build up in lupus nephritis. 
Apoptotic bodies are a source of self antigen, which in turn leads to release of 
pathogenic antibodies into the circulation. Pathogenic antibodies then form immune 
complexes and along with nucleosomes get deposited in various organs. This is where 
the inflammatory mediators contribute to the pathology of lupus. Initiation of 
inflammatory reaction is characterised by expression of cytokines, chemokines, and 
hyper-infiltration of immune cells. In chronic inflammatory conditions like lupus 
nephritis leukocytes leave the intravascular compartment and exit into the interstitium. 
A series of distinct molecular interactions between the monocyte and the lining 
vascular endothelium are essential in this process. Certain molecules presented by 
vascular endothelial cells on their luminal surface represent the ‘signs’ that indicate 
the monocyte to slow down. Transient interactions of E- and L-selectins of the 
endothelium and the monocyte surface reduce the monocyte flow velocity and appears 
like cells slowly rolling on a sticky surface upon flow chamber or in vivo microscopy. 
These transient interactions are required to eventually enable the binding of 
chemokines that are presented on the luminal surface of endothelial cells with their 
respective chemokine receptors on the monocyte. This process is necessary to activate 
members of the β2-integrin family such as leukocyte function-associated antigen-1 
(LFA-1) (αMβ2, CD11a/CD18) and Mac-1 (αMβ2, CD11b/CD18) on the macrophage 
surface. Upon activation these can interact with endothelial counter-receptors such as 
ICAM-1 and surface-associated fibrinogen which enables full adhesion appearing as 
monocyte arrest on microscopy. The subsequent monocyte transmigration into the 
interstitium involves additional molecules that either facilitate transcellular or 
paracellular migration, the latter requiring the opening and closing of endothelial cell-
endothelial cell interactions including tight junctions. 
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Table 2:     Mediators of cell migration as novel anti inflammatory targets. 
Target Drug Company (Status of 
the compound) 
Refs 
Selectins    
E-, P- and L-selectin 
antagonist 
TBC1269 (Bimosiamose) Revotar (Phase II) 
 
Aydt E (2002) 
E-, P- and L-selectin 
antagonist 
OC229648 Ontogen, (Preclinical 
2003) 
Kanebo 
Slee D (2001) 
E-, P- and L-selectin 
antagonist 
Efomycine M Bayer, (Preclinical 2003) 
 
Schon MP (2002) 
Humanized mAb against 
P- and E-selectin 
HuEP5C7 (Smart™) Protein 
Design Labs (Phase II) 
Mocco J (2002) 
mAb against P-selectin CY1747 (PB 1.3) Epimmune (Preclinical 
2001) 
Lefer DJ (2000) 
mAb against L-selectin DREG200 Boehringer (Preclinical 
2001) 
Lefer DJ (2000) 
β  integrins (CD18) 2    
Humanized mAb against 
the β2 integrins 
Rovelizumab Icos, Phase III (halted 
2002) 
Faxon D (2002) 
Humanized mAb against 
β2 integrins 
Erlizumab Genentech Roche Phase 
II (halted 
2001) 
Baran KW (2001) 
α  integrin (CD11a) L    
Murine mAb against the 
αL integrin (CD11a) 
Odulimomab Aventis Pasteur Sangstat 
Launched in France 
(1997) 
Dedrick RL (2003) 
Humanized mAb against 
αL integrin 
Efazulimab Genentech Xoma 
Awaiting FDA and 
EMEA (2003) 
 
Antagonist of the αL 
integrin 
ICI747 Icos, Biogen Phase II 
(2002) 
 
Antagonist of the αL 
integrin 
BIRT377 Boehringer (Preclinical 
2001) 
Yusuf H (2002) 
Antagonist of the αL 
integrin 
 
A304470 Abbott Preclinical (2001) Pei Z (2001) 
α4 integrins (CD49d)    
mAb against α4 integrin 
(CD49d) 
Natalizumab Elan, Biogen, Approved Miller DH (2003) 
Small peptide antagonist 
of α4β1 (CD29/CD49d) 
and α4β7 integrins 
TR14035 Tanabe Seiyaku Phase II 
2003 
Kudlacz E (2002) 
Humanized mAb against 
α4β7 integrin 
MLUPUS NEPHRITIS02 
(LDP02) 
Genentech Millenium 
Phase II 2003 
van Assche G (2002) 
Antagonist of α4β1 
integrin 
 
TBC4746 Encysive Schering 
Preclinical 2003 
Yang  G (2003) 
ICAM-1 (CD54)    
Antisense nucleotide to 
ICAM-1 
ISIS2302 Isis Phase III 2003 Forbes A  (2003) 
Inhibitors of ICAM-1 and 
E-selectin expression 
 
A205804 Abbott Icos Preclinical 
2002 
Zhu D (2001) 
Others    
mAb PECAM-1 mAb PECAM-1 preclinical Vaporciyan, A (1993) 
mAb JAM-A mAb BV-11 preclinical Khandoga, A (2005) 
soluble JAM-C (sJAM-C) soluble JAM-C preclinical Scheiermann (2009) 
anti-CD99 monoclonal 
antibody 
 mAb CD99 preclinical Dufour EM (2008) 
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1.1.2.10 Role of chemokines  
All types of renal cells can express chemokines upon stimulation. The regulatory role 
of chemokines for leukocyte recruitment during inflammatory tissue injury has gained 
most interest over the last decade. In the kidney, all types of renal cells have been 
shown to produce inflammatory chemokines upon various kinds of injury, including 
CCL2, CCL3, CCL4, CCL5 or CXCL10. Local production of these chemokines 
initiates recruitment of macrophages, natural killer cells and T-cell subsets, which 
leads to subsequent glomerulonephritis in the glomerular compartment and to 
interstitial nephritis in the tubulointerstitium. Secreted chemokines bind to endothelial 
surfaces or interstitial matrix components and mediate leukocyte migration through 
their corresponding CCR on the surface of the leukocyte. The specificity of recruiting 
a particular leukocyte subset is provided by specific surface expression patterns of 
CCR. For example, neutrophils but not macrophages express CXCR1, which 
facilitates recruitment upon recognition of the neutrophil attractant chemokine 
CXCL8. Glomerular and interstitial leukocyte recruitment is regulated by different 
chemokines. CCL5 is critical for glomerular macrophage recruitment, as CCL5 
blockade reduces glomerular macrophage counts during immune complex 
glomerulonephritis (Anders HJ. et al.2003), but CCL5  blockade or lack of the CCL5 
receptor CCR5 has no effect on interstitial macrophage and T-cell accumulation after 
unilateral ureteral obstruction (Eis V. et al. 2004).  
In contrast, CCR1 is critical for interstitial macrophage and T-cell recruitment during 
progressive lupus nephritis, but CCR1 blockade does not affect the number of 
glomerular macrophages in murine model of lupus nephritis (Anders HJ. et al.2004). 
In this study Anders et al. (2004) could show prevention of disease progression with 
late onset of CCR1 antagonist treatment which explains a role of CCR1 other than 
mediating leukocyte recruitment. Another target for therapeutic intervention in kidney 
disease is CCL2. Deletion of the CCL2 gene dramatically reduced tubulointerstitial 
injury in mice with nephrotoxic serum nephritis or lupus nephritis of MRLlpr/lpr mice 
(Tesch GH. et al. 1999a,1999b). 
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Figure 4: Hypothetical model of the role of chemokines and chemokine receptors during 
progressive renal diseases. (A) Normal renal tissue. (B) Initiation phase. (C) Amplification 
phase. (D) Progression phase. (Segerer et.al. 2000) 
 
Gene transfer of a truncated human CCL2 protein demonstrated beneficial effects in 
renal fibrosis after unilateral ureteral obstruction in mice (Wada T. et al.2004), 
protein-overload disease in rats (Shimizu H. et al.2003), ischaemic acute renal failure 
in mice (Furuichi K. et al.2003) and in MRLlpr/lpr mice with lupus nephritis (Hasegawa 
H. et al.2003). Epidemiological studies in renal transplant recipients with mutations in 
chemokine or CCR genes support the relevance of such rodent data in human kidney 
disease (Fischereder M. et al.2001, Kruger B. et al.2002). These data suggest that 
interstitial fibrosis, the common final pathway of most chronic nephropathies, may be 
susceptible for therapeutic blockade of selected chemokines or chemokine receptors 
CCL2 in nephritis 
There is an increasing body of evidence that the CC chemokine monocyte 
chemoattractant protein-1 (CCL2) plays a major role in the pathogenesis of 
progression of renal failure. This is based on observations both in various animal 
models of renal damage and in different types of human renal disease. Locally 
produced CCL2 seems to be particularly involved in the initiation and progression of 
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tubulointerstitial damage. The latter has been documented in experiments using 
transgenic mice with nephrotic serum-induced nephritis: compared with wild-type 
mice, CCL2-deficient mice exhibit less tubulointerstitial lesions, but they exhibit no 
differences in glomerular lesions (Tesch GH. et al.1999a). There is, however, evidence 
that CCL2 also plays a role in the progression of glomerular lesions, since glomerular 
expression of CCL2 correlates with the degree of renal damage in inflammatory 
(Panzer U. et al.2001) and non-inflammatory (Taal MW. et al.2000) models of 
glomerular injury. Furthermore, in humans with crescentic glomerulonephritis, CCL2 
is not only expressed in tubular epithelial cells and leukocytes infiltrating the 
tubulointerstitium, but also in crescents and parietal epithelium (Segerer S. et al.2000). 
In experimental crescentic glomerulonephritis, administration of antibodies to CCL2 
decreases the extent of proteinuria, reduces glomerulosclerosis and improves renal 
dysfunction. CCL2, a potent chemoattractant for monocytes and for T cells, is secreted 
from many kinds of renal cells, including endothelial, mesangial, tubular epithelial and 
interstitial cells, and macrophages, in response to stimulation with proinflammatory 
cytokines and immune complexes. A significant number of T cells and macrophages 
infiltrate the kidneys of patients with lupus nephritis. Overexpression of CCL2 in renal 
tissue parallels mononuclear cell accumulation (Tesch GH. et al.1999b, Perez de Lema 
G. et al. 2001). In biopsy samples from patients with lupus nephritis, the presence of 
CCL2 has been observed in endothelial cells, macrophages, mesangial cells, and 
tubular epithelial cells (Rovin BH. et al.1994). In addition, it has been reported that 
elevated urinary CCL2 excretion reflects lupus nephritis disease activity (Noris M et 
al. 1995). These findings suggest that overexpression of CCL2 plays an important role 
in the pathogenesis of lupus nephritis in humans and in animal models. In lupus 
nephritis, production of CCL2 in the many types of renal cells described above is 
triggered by the deposition of ICs and complement activation, and subsequently leads 
to mononuclear cell infiltration. Moreover, after CCL2 production by local cells, the 
infiltrating macrophages become a source of CCL2, resulting in an amplification loop. 
1.1.3 Biology behind therapy for lupus nephritis 
Since lupus nephritis is a chronic disease with no known cure, its treatment is 
restricted to dealing with symptoms, that is, management of inflammatory reactions by 
suppression of the activity of the patient’s immune system. This is done mainly with 
steroids alone or in combination with other durgs. Mild or remittent disease may 
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sometimes be left untreated, but patients should avoid sun exposure. If required 
NSAIDs or anti-malarial may be used. 
 
Immune dysregulation 
 
Figure 5: Current therapy and novel therapeutic approaches for lupus. 
 
Anti-malarial and immunosuppressants are used preventively to reduce incidence of 
flares, the process of the disease and to lower the need of steroid use. In more severe 
cases, corticosteroids and immunosuppressant, drugs that modulate immune system, 
are used to control the disease and prevent flares. Since immunosuppressant drugs can 
have serious side effects, they are mainly used only for patients with severe systemic 
disease or organ failure (e.g. nephritis). Cyclophosphamide (CYC), MMF, 
azathioprine are the first line immunosuppressant drugs for treatment of lupus 
nephritis. Beside steroids hydroxycloroquine or azathioprine is sometimes used to 
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control lupus during pregnancy since these drugs appear to have fewer risks to the 
foetus than other drugs. 
Lupus patients are more susceptible to infections, since both lupus and its treatments, 
in particular corticosteroids and immunosuppressive drugs, affect the immune system. 
Infections can induce lupus flare, which further increases the risk of infection. Finally 
lupus appears to increase the risk of cancer, especially non-Hodgkin’s lymphoma, 
which affects the lymphoid organs. Immunosuppressive drugs used to treat lupus can 
also enhance the risk of cancer. Thus the main goal of research is to find drugs to treat 
lupus more specifically, without systemically suppressing the immune system. 
Treatments, that are more specific in modifying particular subsets of immune cells 
(e.g. T/B cells), or the activity of cytokine they secret have been gaining attention. 
Biological agents targeting B cells are under development including a fully humanised 
anti-CD20 antibody (Rituximab), an anti-CD22 antibody (Epratuzumab) and a number 
of molecules blocking BlyS have been developed. The human anti-BlyS antibody 
(Belimumab) is currently in a phase III study. BlyS (also called BAFF) is a soluble 
mediator that plays a role in the regulation of B-cell homeostasis and differentiation. 
The three known receptors for BlyS are differentially expressed at various stages of B-
cell and plasma cell development suggesting that the consequences of BlyS blockade 
may differ from B-cell depletion by anti-CD20 treatment (Treml et al.2006). 
A variety of co-stimulatory ligand/receptor pairs have been described that modulate 
the interaction of dendritic cells and T cells, or T cells and B cells, respectively. The 
first family of these to be discovered was the B7 family. CTLA-4-Ig is a drug that 
blocks the interaction of CD80 and CD86 on antigen-presenting cells with CD28 on T 
cells and has negative regulatory effects. CTLA-4-Ig has been approved for the 
treatment of RA after recent successful RCTs (Todd et al.2007). It has also been 
demonstrated to block nephritis in a mouse model of SLE (Cunnane et al. 2004) and 
human studies are ongoing. There were 3 trials with anti-CD40L mAb IDEC-131, 
enrolling in global 110 lupus patients, although not all had with nephritis (Huang et 
al.2002, Davis Jr et al.2001) and one with BG9588 which included 28 patients with 
active proliferative lupus nephritis (Boumpas et al. 2003). In summary the results 
failed to demonstrate significant drug benefit compared to placebo in terms of time to 
renal flare, SLE disease activity index (SLEDAI) and serologic markers (complement 
and anti-DNA Ab) (Kalunian et al.2002). The study with BG9588 was prematurely 
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terminated due to the increased occurrence of thromboembolic events despite 
concurrent prophylactic anticoagulation (Boumpas et al.2003, Kawai et al.2000). 
A very different approach is to try modulating the autoimmune process in SLE in an 
antigen-specific way. Abetimus is a molecule composed of a series of linked 
oligonucleotides. The concept behind Abetimus is that the drug will block the binding 
of anti dsDNA antibodies to their autoimmune targets and/ or will tolerise B cell with 
antigen-specificity for DNA (Alarcon-Segovia et al.2003). Results in clinical trials 
have been very modest so far. Edratide represents a similar approach. Edratide is a 
peptide derived from the antigen-binding region of a human monoclonal anti-dsDNA 
antibody (Sharabi et al. 2007). It has been proposed that this molecule can modulate 
the function of DNA-reactive B cells through idiotype–anti-idiotype interactions. 
Even though T cells and B cells targets seem to promising, clinical trail results for 
these therapies do not look encouraging (see table). This leaves scope for the 
development of new strategies to encounter lupus nephritis. 
 
Table 3: SLE trail data for new biological therapies  
Target Treatment In mouse mdoel In humans 
T cells    
CD28/B7 costimulation 
blockade 
Abatacept Effective  
(Ramanujam M. et al. 
2004) 
End points not met 
(Westhovens R. et al. 2008) 
CD40 and CD40-L BJ9588 
 
 
Anti-CD154 
Effective 
(Wang X. et al. 2003) 
Trial stopped for side effects 
(Boumpas DT. et al. 2003) 
End points not met 
(Kalunian KC. et al. 2002) 
ICOS and ICOS-L Anti-ICOS L antibody Effective 
(Iwai H et al. 2003) 
 
B cells    
CD22 Epratuzumab  Effective 
(Dorner T. et al. 2006) 
CD20 Rituximab  End points not met 
(Explorer Trail) 
Anti metabolite MMF  End points not met 
(ALMS study) 
Multivalent 
DNA 
Abetimus  End points not met 
(Cardiel MH. et al. 2008) 
Anti-BAFF Belimumab  End points not met 
(Wallace DJ. et al. 2009) 
 
Targeting CCL2 in lupus 
As we have reviewed in early part of this introduction CCL2 presents an exciting 
target to attenuate lupus nephritis particularly in controlling the inflammatory cascade 
of the lupus pathogenesis. To block CCL2 and its receptor (CCR2) signalling pathway 
Shimizu et al. (2004) used the strategy of anti-CCL2 gene therapy involving the 
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transfection of a mutant human CCL2 gene into skeletal muscle. This mutant human 
CCL2, designated 7ND, lacks NH2-terminal amino acids 2–8 and has been shown to 
work as a dominant-negative inhibitor of human CCL2. Histological findings of 
kidneys in treated mice with 7ND showed that protection against renal injury resulted 
from reduced infiltration of leucocytes. 7ND gene therapy was shown to prolong the 
life span of MRLlpr/lpr mice (Shimizu S et al 2004). Another group (Hagesawa et al. 
2003) injected CCL2 antagonist- or TARC antagonist-transfected MRL/N-1 cells 
subcutaneously into MRLlpr/lpr mice ages 7 weeks (before the onset of lupus nephritis) 
and 12 weeks (at the early stage of the disease). After 8 weeks, mice bearing the CCL2 
antagonist showed markedly diminished infiltration of macrophages and T cells, 
glomerular hypercellularity, glomerulosclerosis, crescent formation, and vasculitis 
compared with control mice. Authors concluded that the effect was due to decreased 
production of interferon-  and IL-2 in the kidney. However, such experimental 
approaches cannot be used in humans because of irrepressible antagonist production 
and tumor formation (Shimizu S et al.2004, Hagesawa et al.2003). 
Following these impressive findings we thought of targeting CCL2 blockade with a 
clinically applicable approach. Spiegelmer technology based aptamers rose to the 
occasion as these are safe, biostable and specifically binding to the target. 
 
1.2. Spiegelmers: Next generation aptamers 
To achieve CCL2 antagonism we used a RNA-aptamers (Spiegelmer), a patented 
technology of NOXXON Pharma (Berlin). RNA-aptamer binds to the active site of 
target chemokine and makes them biologically non-functional.  
An aptamer is a nucleic acid structure that can bind to a target molecule conceptually 
similar to an antibody that recognizes an antigen. Aptamers have binding 
characteristics similar to peptides or antibodies, with affinities in the low nanomolar to 
the picomolar range. However, there are several drawbacks to aptamers as useful 
therapeutic products. As relatively small molecules, aptamers demonstrate circulating 
half-lives in vivo in the order of minutes. This situation can be addressed by attaching 
large inert molecules to aptamers (e.g. polyethylene glycol) to reduce their elimination 
via the kidney and increase their presence in the circulation. Still, aptamers, as natural 
nucleic acid polymers, are prone to rapid degradation by nucleases that are present in 
all tissues in the body.  
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Spiegelmers are biostable aptamers, that have all of the diverse characteristics of 
aptamers and possess a structure that prevents enzymatic degradation. While 
conventional aptamers are created from the natural D-nucleotides, which are 
recognized by the nucleic acid degrading enzymes, Spiegelmers are synthesized from 
mirror image L-oligonucleotide and hence they can not be degraded by any nucleases 
since there are no such enzymes in the body capable of interacting with these 
unnatural molecules. Spiegelmer technology is based on the simple concept that if an 
aptamer binds its natural target, the mirror image of the aptamer will identically bind 
the mirror image of the natural target (Figure 6). The process of aptamer selection is 
carried out against the mirror image target protein; an aptamer against this unnatural 
mirror image is obtained. More important, this Spiegelmer is now resistant to nuclease 
degradation. Spiegelmers should not be confused with antisense RNAs in that they do 
not directly interfere with transcription or translation of their target molecules. They 
are designed to bind specifically to extracellular proteins, either a receptor or its 
ligand, similar to the behavior of a monoclonal antibody, aptamer or peptide. 
Spiegelmers appear to be non-immunogenic, even under the most inductive conditions 
for antibody formation in rabbits. These molecules are termed “Spiegelmer” from the 
German word “Spiegel” meaning “mirror”. 
Spiegelmers possess the high affinity binding characteristics of the best aptamers and 
antibodies in the low nanomolar and picomolar range, while defying enzymatic 
degradation that severely limits the utility of aptamers (Klussmann S. et al.1996). Data 
indicate that Spiegelmers are stable in human plasma for over 60 hours at 37 °C 
(Figure 7.) while non-modified RNA aptamers are degraded in seconds under the same 
conditions (left panel, Figure. 7). Results in animals indicate that a similar stability can 
be expected in vivo as well 
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Figure 6: Representation of Spiegelmer generation. L-enantiomer of the target is processed to 
get the selective binding D-aptamer. Highly selective D-aptamer for mirror image (L-target) is 
then amplified and then mirrored to get L-aptamer which has the selective binding property for 
natural D-target. (Taken from www.noxxon.net) 
   
 
 
 
Figure 7: Representation of Spiegelmer stability. Left panel with D-enantiomeric RNA which 
degrades in seconds when incubated in human plasma at 37°C., while L-enantiomeric RNA is 
stable even at 60 hrs of incubation in human plasma (right panel) 
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Summary of Spiegelmer Properties 
• high binding specificity to their target 
• comparable binding affinity as antibodies (low nanomolar-picomolar) 
• stable in human plasma and after injection into animals 
• non-immunogenic 
• low toxicity (target-based) 
• synthesized using standard chemistry (scalable) 
• no biological contaminants 
• easy to formulate (polar) with excellent solubility 
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1.3 MRL lpr/lpr mice:mouse model of lupus nephritis 
 
MRLlpr/lpr mice lack functional expression of the apoptosis-inducing receptor Fas, 
thereby accelerating the manifestation of the autoimmune disease, which also develops 
in wild-type MRLlpr/lpr mice, albeit, with a slower kinetic. MRLlpr/lpr mice show 
systemic autoimmunity, massive lymphadenopathy associated with proliferation of 
abberrant CD3+B220+CD4-CD8- T cells and immune complex-derived 
glomerulonephritis. Starting at approximately 3 months of age, levels of circulating 
immune complexes, such as those from spontaneously generated anti-dsDNA 
antibodies, rise dramatically in MRLlpr/lpr but not in wild-type MRL controls. Lymph 
node weight of MRLlpr/lpr increases approximately 75-fold over controls and renal 
pathology occurs extensively in MRLlpr/lpr at approximately 4 months of age. In 
MRL/lpr mice, a proliferative glomerulonephritis is seen, with mononuclear cell 
infiltration, endothelial and mesangial cell proliferation, and crescent formation 
(Cohen PL., Eisenberg 1991). Finally, female MRLlpr/lpr mice die at an average of 
17 weeks of age and males at 22 weeks. 
 
 
 
 
Figure 8: MRLlpr/lpr mice life span and progression of autoimmune phenotype. 
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2. Research hypothesis/objectives 
 
1. The role of CCL2/CCR2 axis in chronic inflammatory conditions is well 
known. But so far there is no therapy in the clinics which attenuate the inflammation 
mediated by CCL2, even though lots of efforts are being made. Gene therapy against 
CCL2 can suppress nephritis. in murine model of lupus nephritis (Hagesawa et 
al.2004). But these kinds of approaches are not clinically applicable, as these 
represent irreversible antagonism and have been reported for side effects. 
Considering these facts in mind our first ojective was to evaluate the efficacy of an 
anti-CCL2 Spiegelmer (mNOX-E36). 
 
2. Second objective was to compare the efficacy of Anti-CCL2 Spiegelmer 
(mNOX-E36) with that of cyclophosphamide and MMF. 
 
3. Immunosuppressants like CYC and MMF effectively control rapidly 
progressing lupus. But with high exposure of immunotherapies there is always a 
possiblity of adverse effects. In clinical practice lots of patients experienced 
infections, gonadal toxicities and other side effects which are even fatal in some 
cases. That is why lots of efforts are being made to discover novel ways to combat 
lupus nephritis. T cell and B cells based therapies did not show any promising 
results. Considering all these findings we thought of combining anti-CCL2 
Spiegelmer with low dose of CYC and then comparing it high dose of CYC for its 
efficacy as well as safety. 
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3. Materials and Methods 
3.1 Materials 
Equipments  
Balances: 
Analytic Balance, BP 110 S   Sartorius, Göttingen, Germany 
Mettler PJ 3000    Mettler-Toledo, Greifensee,Switzerland 
Cell Incubators: 
Type B5060 EC-CO2    Heraeus Sepatech, München, Germany 
Centrifuges: 
Heraeus, Minifuge T    VWR Internationl, Darmstadt, Germany 
Heraeus, Biofuge primo                       Kendro Laboratory Products GmbH, 
      Hanau, Germany 
Heraeus, Sepatech Biofuge A   Heraeus Sepatech, München, Germany 
ELISA-Reader 
Tecan, GENios Plus        Tecan, Crailsheim, Germany 
Fluorescence Microsocopes 
Leica DC 300F                                     Leica Microsystems, Cambridge, UK  
Olympus BX50                                     Olympus Microscopy, Hamburg,  
      Germany 
Spectrophotometer 
Beckman DU® 530    Beckman Coulter, Fullerton, CA, USA 
TaqMan Sequence Detection System  
ABI prism ™ 7700 sequence  
detector      PE Biosystems, Weiterstadt, Germany 
Other Equipments 
Cryostat RM2155    Leica Microsystems, Bensheim,  
      Germany 
Cryostat CM 3000    Leica Microsystems, Bensheim,  
      Germany 
Homogenizer ULTRA-TURRAX  
T25      IKA GmbH, Staufen, Germany  
Microtome HM 340E    Microm, Heidelberg, Germany 
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pH meter WTW     WTW GmbH, Weilheim, Germany 
Thermomixer 5436    Eppendorf, Hamburg, Germany 
Vortex Genie 2™    Bender&Hobein AG, Zurich,  
       Switzerland 
Water bath HI 1210    Leica Microsystems, Bensheim,  
       Germany 
 
Chemicals and materials 
Chemicals for the molecular biology techniques 
RNeasy Mini Kit    Qiagen GmbH, Hilden, Germany 
RT-PCR primers     PE Biosystems, Weiterstadt, Germany 
 
Cell culture  
DMEM-medium                                    Biochrom KG, Berlin, Germany  
RPMI-1640 medium    GIBCO/Invitrogen, Paisley, Scotland, UK 
FSC      Biochrom KG, Berlin, Germany 
Dulbecco’s PBS (1×)    PAA Laboratories GmbH,   
      Cölbe,Germany 
Trypsine/EDTA (1×)     PAA Laboratories GmbH,   
      Cölbe,Germany 
Penicillin/Streptomycin (100×)  PAA Laboratories GmbH,   
      Cölbe,Germany 
 
Antibodies  
rat anti-Mac2     Cederlane, Ontario, Canada 
anti-CD3      BD Pharmingen, Hamburg, Germany 
anti-CD4      BD Pharmingen, Hamburg, Germany 
anti-CD8      BD Pharmingen, Hamburg, Germany 
anti-CD25      BD Pharmingen, Hamburg, Germany 
anti-CD45     BD Pharmingen, Hamburg, Germany 
anti-7/4      Abd-Serotec, 
anti-Ly6G      BD Pharmingen, Hamburg, Germany 
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Miscellaneous 
Needles      BD Drogheda, Ireland 
Pipette’s tip 1-1000μL                            Eppendorf, Hamburg, Germany 
Plastic histosettes    NeoLab, Heidelberg, Germany 
Preseparation filters    Miltenyi Biotec, Bergish Gladbach,  
       Germany 
SuperFrost Plus  
microscope slides                                Menzel-Gläser, Braunschweig,  
       Germany 
Silver Impregnation Kit   Bio-Optica, Milano, Italy 
Syringes                                              Becton Dickinson GmbH, Germany 
 
Chemicals  
Aceton                                                  Merck, Darmstadt, Germany  
AEC Substrat Packung                          Biogenex, San Ramon, USA  
Ether                                                     Merck, Darmstadt, Germany  
Bovines Serum Albumin                       Roche Diagnostics, Mannheim,Germany 
Cyclophosphamide  Sigma-Aldrich Chemicals,   
  Steinheim,Germany  
DEPC                                                    Fluka, Buchs, Switzerland 
DMSO                                                   Merck, Darmstadt, Germany 
EDTA                                                    Calbiochem, SanDiego, USA 
Ethanol                                                  Merck, Darmstadt, Germany 
Formalin                                                Merck, Darmstadt, Germany  
Hydroxyethyl cellulose                           Sigma-Aldrich, Steinheim, Germany 
HCl (5N)                                                 Merck, Darmstadt, Germany 
Isopropanol                                            Merck, Darmstadt, Germany 
Kaliumchlorid                                         Merck, Darmstadt, Germany  
Kaliumdihydrogenphosphat                   Merck, Darmstadt, Germany 
Kaliumhydroxid                                      Merck, Darmstadt, Germany 
MACS-Puffer                                         Miltenyi Biotec, Bergisch Gladbach, 
  Germany 
Merkaptoethanol                                   Roth, Karlsruhe, Germany 
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Natriumacetat                                        Merck, Darmstadt, Germany  
Natriumchlorid  Merck, Darmstadt, Germany 
Natriumcitrat  Merck, Darmstadt, Germany 
Natriumdihydrogenphosphat  Merck, Darmstadt, Germany 
Penicillin  Sigma, Deisenhofen, Germany 
Roti-Aqua-Phenol  Carl Roth GmbH, Karlsruhe, Germany 
SSC (Saline-sodium citrate Puffer)  Sigma, Deisenhofen, Germany 
Tissue Freezing Medium   Leica, Nussloch, Germany 
Trypan Blue  Sigma, Deisenhofen, Germany 
Oxygenated water  DAKO, Hamburg, Germany  
Xylol  Merck, Darmstadt, Germany  
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3.2. Methods 
 
3.2.1 Methods Part I 
 
3.2.1.1 Grouping and treatment 
Seven week old female MRLlpr/lpr mice were obtained from Harlan Winkelmann 
(Borchen, Germany) and kept in filter top cages under a 12 hour light and dark cycle. 
Water and standard chow (Sniff, Soest, Germany) were available ad libitum. All 
experimental procedures were approved by the local government authorities. At the age 
of 14 week, female MRLlpr/lpr mice were distributed into seven groups that received 
subcutaneous injections every alternate day as follows: 
 
Table: 4 Treatment protocol I 
   
Group   Treatment Dosage  level 
a(mg/kg) 
Dose 
volume 
(ml/kg) 
Treatment 
Schedule 
 
no 
1 Vehicle (5% Glucose) 0 4 3 times/week 12 
2 POC 25 4 3 times/week 12 
3 POC-PEG 50 4 3 times/week 12 
4 mNOX-E36 25 4 3 times/week 12 
5 mNOX-E36-PEG 50 4 3 times/week 12 
6 mNOX-E36 (PKa) 25 4 3 times/week 12 
7 mNOX-E36-PEG 
(PKa) 
50 4 3 times/week 12 
Pka = Satellite animals for pharmacokinetics;  
a = in vivo doses of mNOX-E36 and POC-PEG in mg/kg apply to the combined total weight of 
the oligonucleotide part plus the coupled PEG moiety. Thus, mNOX-E36 has to be multiplied 
with the factor 0.29. 
All Spiegelmer samples were provided by Noxxon Pharma AG, in ready to use formulation.  
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3.2.1.2 Route and rationale of test material administration 
The chosen route of administration was subcutaneous, as the animals tolerate a large 
number of subcutaneous administrations better than numerous intraperitoneal 
injections, handling is easier and because by this route unPEGylated Spiegelmer is 
present longer in the circulation. 
 
3.2.1.3 Test substance and formulation 
Spiegelmer    Sequence 
mNOX-E36   5`-GGCGACAUUG GUUGGGCAUG 
    AGGCGAGGCC CUUUGAUGAA 
    UCCGCGGCCA-3` 
mNOX-E36-PEG  40 kD PEG 
    5`-GGCGACAUUG GUUGGGCAUG 
    AGGCGAGGCC CUUUGAUGAA 
    UCCGCGGCCA-3` 
Control Spiegelmer  Sequence 
POC    5`-UAAGGAAACU CGGUCUGAUG 
    CGGUAGCGCU GUGCAGAGCU-3` 
POC-PEG   40 kD PEG 
    5`-UAAGGAAACU CGGUCUGAUG 
    CGGUAGCGCU GUGCAGAGCU-3` 
  
For in vivo application, the mNOX-E36 and the non-functional control Spiegelmer 
POC were used non-modified or modified with 40-kD PEG at the 3` and 5` terminus, 
respectively. The test substance (Spiegelmer solution) was dissolved in isotonic 5 % 
glucose solution 
 
3.2.1.4 Mortality, clinical signs, skin score and body weight 
Mortality was recorded every week throughout the study. Animals were observed daily 
for clinical signs. In addition, MRLlpr/lpr mice of all groups were checked daily for 
cutaneous lupus manifestations, which typically occur in the facial or neck area. The 
severity was graded from 0 – 0.5 (no lesion), 1 (mild lesion), 2 (moderate) to 3 (severe) 
After 10 weeks of treatment, satellite animals for pharmacokinetics were kept alive in 
order to monitor survival rate. Body weight was recorded once a week during weeks 14 
to 24 of age (10 weeks of treatment). 
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3.2.1.5 Pharmacokinetic analysis 
In week 1, 5 and 10 of treatment, blood samples for pharmacokinetic analysis were 
collected in satellite animals at the following times: 
- mNOX-E36 (25 mg/kg) at 0.083, 0.33, 0.66, 1, 3, 9, 12 and 24 hours after injection; 
- mNOX-E36-P (50 mg/kg) at 3, 6, 9, 12, 24, 30, 36 and 48 hours after injection. 
To correlate the pharmacokinetic alteration with the progression of the disease, 
additional samples were taken 3 hours post administration for unPEGylated mNOX-
E36 (25 mg/kg) and 24 hours post administration for mNOX-E36 (50 mg/kg), after the 
first dose of the week. All samples were stored at –20 ºC until analysed by method 
described below. 
For immobilization of the Spiegelmer an L-RNA capture probe (CP) which is 
complemantary (base-pairing) to one end of the analyte Spiegelmer is covalently 
coupled to a 96-well plate. After hybridization (base-pairing) of the analyte Spiegelmer 
to this capture probe, a second (biotinylated) L-RNA probe ("detect probe", DP) is 
hybridized (base-pairing) to the second end of the analyte. After unbound complexes 
have been removed, the complex of Spiegelmer and detect probe is detected by a 
streptavidine/alkaline phosphatase conjugate converting a chemiluminescence 
substrate.  
 
3.2.1.6 Glomerular filtration rate 
Preparation of 5% FITC-inulin solution 
5% FITC-inulin was dissolved in two ml of 0.9% NaCl -- facilitated by heating the 
solution in boiling water.  
Intravenous injection and blood collection 
Mice were anesthetized using Isoflurane, which for approximately 20 seconds. 5% 
FITC-inulin (3.74μl /g body weight) was injected retroorbitally under anesthesia within 
10 seconds. Under general anaesthesia, blood was drawn from the retro orbital plexus 
at 5, 10, 15, 20, 35, 60 and 90 minutes post administration. 
Determination of fluorescence of the sampled plasma 
Since pH significantly affects FITC fluorescence value, each plasma sample was 
buffered to pH 7.4, by mixing 10 μl of plasma with 40 μl of 500 mM HEPES (pH 7.4). 
The titrated samples were then loaded onto a 96-well plate, 50μl sample/well. 
Fluorescence was determined with 485 nm excitation, and read at 538 nm emission.  
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Calculation of GFR  
A two – compartment clearance model may be employed for the calculation of GFR. In 
the two-compartment model used, depicted in Figure 9, the initial, rapid decay phase 
represents redistribution of the tracer from the intravascular compartment to the 
extracellular fluid. Systemic elimination also occurs, but the distribution process is 
relatively dominant during this initial phase. During the later, slower decay in 
concentration of the tracer systemic clearance of the tracer from the plasma 
predominates. At any given time (tX), the plasma concentration of the tracer (Y) equals 
to Ae 
-αtx 
+ Be 
-βtx 
+Plateau 
 
Figure 9: Representation two phase regression curve  
 
The parameters of above equation could be calculated using a non-linear regression 
curve-fitting program (GraphPad Prism, GraphPad Software, Inc., San Diego, CA.). 
GFR was calculated using the equation:  
GFR= I/(A/α + B/β),   
Where I is the amount of FITC-inulin delivered by the bolus injection; A (Span1) and 
B (Span2) are the y -intercept values of the two decay rates, and α and β are the decay 
constants for the distribution and elimination phases, respectively. 
 
3.2.1.7 Plasma, urine and tissue collection 
After 10 weeks of treatment (on the day of sacrifice), blood samples were collected 
under ether anaesthesia 2 to 3 hours after the last administration. Blood was drawn by 
retroorbital bleeding using heparinised capillaries. Plasma was separated by 
centrifugation at 10,000 rpm for 5 minutes. 
Urine samples were collected when the animals were 16, 21 and 24 weeks of age. 
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At study termination (at the end of the 10-week treatment period), organ weights of 
spleen and lymph nodes were determined. Spleen, lymph nodes, kidney, lung, liver, 
and salivary gland tissue samples were collected from each mouse for histology, RNA 
analysis. 
 
3.2.1.8 Histology of kidney and lungs 
Morphological and histological processing  
From all mice, the tissues were isolated from kidneys or spleens and placed in plastic 
histocassettes and immediately fixed in 10% buffered formalin (formaldehyde in PBS) 
for overnight and next day processed, with automatic tissue-processor (Thermo- 
Shandon), which processes tissues in following manner- 70% ethanol (for 5 hours), 96 
% ethanol (2 hrs), 100 % ethanol 3.5 hrs, xylene (2.5 hrs), paraffin (4 hrs). Then the 
histocassettes were taken out and the paraffin blocks were prepared with hot liquid 
paraffin using a machine (Microm- EC 350). The prepared blocks were allowed to cool 
down and later separated from the steel holders. These blocks were later used for 
making fine sections for different stainings (PAS or immunohisto). The fine sections 
(5μm) were prepared using the microtome (Microm- HM340E) and mounted gently on 
a glass frosted slide. Such slides were later allowed to dry for 2 hours in an oven at 
50°C temperature. Deparaffinisation followed by dehydration was carried out by 
incubating the sections in xylene, 100% absolute ethanol, 95%, 80% and 50% ethanol 
followed by rinsing with PBS (2 changes, 3 minutes each). 5 μm sections for silver and 
periodic acid-Schiff stains were prepared following routine protocols for 
histopathology. From each mouse tissue collected as mentioned above, 2 μM thick 
paraffin-embedded sections were cut and processed for immunohistochemical staining 
performed on paraffin-embedded sections. 
Analysis of glomerulonephritis  
The severity of the renal lesions was graded using the indices for activity and 
chronicity as described for human lupus nephritis (Austin et al, 1984). Activity index 
was considered as the sum of individual scores of the following items considered to 
represent measures of adaptive lupus nephritis: glomerular proliferation, leucocyte 
exudation, karyorrhexis/fibrinoid necrosis (X2), cellular crescents (X2), hyaline 
deposits, and interstitial inflammation. The maximum score was 24 points for activity 
index. Chronicity index was considered to be the sum of individual scores of the 
following items considered to represent measures of chronic irreversible lupus 
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nephritis: glomerular sclerosis, fibrous crescents, tubular atrophy and interstitial 
fibrosis. The maximum score was 12 points for the chronicity index. 
Immunostaining 
For immunostaining sections of formalin-fixed and paraffin-embedded tissues were 
dewaxed and rehydrated. Endogenous peroxidase was blocked by 3 % hydrogen 
peroxide and antigen retrieval was performed in Antigen Retrieval Solution (Vector, 
Burlingame, CA USA) in an autoclave oven. Biotin was blocked using the Avidin / 
Biotin blocking kit (Vector, Burlingame, CA USA). Slides were incubated with the 
primary antibodies for one hour, followed by biotinylated secondary antibodies (anti-
rat IgG, Vector, Burlingame, CA USA), and the ABC reagent (Vector, Burlingame, CA 
USA). Slides were washed in phosphate buffered saline between the incubation steps. 
3’3’Diaminobenzidine (DAB, Sigma, Taufkirchen, Germany) with metal enhancement 
was used as detection system, resulting in a black coloured product. Methyl green was 
used as counterstain, slides were dehydrated and mounted in Histomount (Zymed 
Laboratories, San Francisco, CA USA). The following primary antibodies were used: 
rat anti-MAC-2 (macrophages, Cederlane, Ontario, Canada, 1:50), anti-mouse CD3 
(1:100, clone 500A2, BD), anti-mouse IgG1 (1:100, M32015, Caltag Laboratories, 
Burlingame, CA USA), anti-mouse IgG2a (1:100, M32215, Caltag Laboratories, 
Burlingame, CA USA). Negative controls included incubation with a respective isotype 
antibody. For quantitative analysis glomerular cells were counted in 15 cortical 
glomeruli per section. Glomerular Ig deposits were scored from 0 – 3 on 15 cortical 
glomerular sections. The indices for interstitial volume, interstitial collagen deposition, 
tubular cell damage, and tubular dilatation were determined by superposing a grid 
containing 100 (10 x 10) sampling points on photographs of 10 nonoverlapping cortical 
fields of silver-stained tissue (x 20) of each kidney. 
3.2.1.9 Biochemical analysis of plasma and urine samples 
Urine albumin (Bethyl Laboratories Inc, Montgomery, TX USA) and creatinine were 
determined using diagnostic kits. Plasma samples were analysed for cytokines (BD 
Pharmingen kits for IL12p40, IL6 and CCL2) and immunoglobulin (Bethyl 
Laboratories Inc, Montgomery, USA) using ELISA kits. Plasma creatinine, albumin, 
urea nitrogen and cholesterol were analysed by SynLab GmbH & Co. KG, Augsburg, 
Germany. 
 
 41
Analysis of plasma autoantibodies 
Serum dsDNA autoantibodies were determined by using commercial ELISA kits 
(Bethyl Labs, Montgomery, TX, USA) using the following antibodies: anti-mouse 
IgG1 and IgG2a following the manufacturer’s protocol with some modifications as 
follows: 
1) Sample wells in NUNC maxisorp 96 well flat bottom ELISA plate were coated 
with 50 μg/ml (dilute in PBS) of the aqueous solution of 100 μl of Poly-L-Lysine 
(Trevigen, Gaithersburg, MD, USA) for 1 hour at room temperature. 
2) Washed once with washing buffer, tap dried on blotting paper and coated the 
sample wells  with 1 μg/ml of dsDNA, which was diluted in SSC buffer (1X), pH 7 . 
3) For standard wells, capture antibody in coating buffer was added as described in 
the protocol. 
4) The plate was incubated overnight at 4°C. 
5) Next day the plate was washed with the wash buffer 3 times and then blocked 
with blocking solution and the protocol was followed as provided by the bethyl labs 
from this blocking step onwards. 
6) Standard dilutions and samples were added in respective wells in required 
dilution and incubated at room temperature for 2 hours. 
7) Plate was washed 3 times and then secondary antibody at given dilution was 
added as per the protocol and incubated for 1 hour at room temperature. 
8) Plate was again washed as before and TMB substrate (1:1 mixture of substrate 
A and B) was added in each well and incubated in dark for 5-20 minutes. 
9)  The reaction was stopped with 1 M H2SO4 and absorbance was measured at 
450 nm. 
 
Protocol for ELISAs (in brief)  
1) The NUNC ELISA plate wells were captured overnight at 4°C with the capture 
antibody in coating buffer.  
2) Next day the plates were washed 3 times with the washing buffer as given in 
protocol for 3 times and blocked with the blocking solution or assay diluent for 1 hour 
or as specified.  
3) Again the washings were repeated 3 times followed by addition of standards; 
samples and sample diluent (blank) into the wells of tap dried plate and incubated at 
RT for 2 hours 
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4) This was followed by washings for 5 times or as specified 
5) Then HRP/AP conjugated secondary antibody diluted in assay diluent was 
added. Incubate the plate as specified. 
6) The wells were washed again for 5-7 times or as specified and incubated with 
the 100 μl of substrate A and B (1:1 mixture) for 25-30 min in dark to develop colour. 
The reaction was stopped by addition of 100 μl 1 M H2SO4.  
7) The reading of the absorbance was taken at 450 nm and the reference 
wavelength was 620 nm using a spectrophotometer (TECAN-Genios Plus). 
 
3.2.1.10 RNA isolation, cDNA synthesis and real time RT-PCR 
Renal tissue from each mouse was snap frozen in liquid nitrogen and stored at -80 °C. 
Real time RT-PCR was performed in pooled samples (5 animals from each group) on a 
TaqMan ABI 7700 Sequence Detection System (PE Biosystems, Weiterstadt, 
Germany) using a heat activated TaqDNA polymerase (Amplitaq Gold, PE 
Biosystems). Controls comprising ddH2O were negative for target and housekeeper 
genes. Primers and probes were from PE Biosystems, Weiterstadt, Germany. 
Oligonucleotide primer (300 nM) and probes (100 nM) were used (primers and probes 
used are mentioned below). From each animal total renal RNA preparation and reverse 
transcription were performed as described. 
Isolation of RNA from tissues 
When animals were sacrificed on termination of the study, small parts of tissue from 
each mouse were preserved in RNA-later and stored at -20 0C until processed for RNA 
isolation. RNA isolation was carried out using RNA isolation kit from Qiagen 
(Germany). In short, tissues (30 mg) preserved in RNA-later were homogenized using 
blade homogenizer for 30 seconds at 14500 rpm in lysis buffer (600 µl) containing β-
mercaptoethanol (10 µl/ml). The homogenate was centrifuged at 15000 rpm for 3 min. 
and 350 µl of supernatant was transferred to fresh DEPC-treated tube to this equal 
amount (350 µl) of 70 % ethanol was added and whole mixture was loaded on RNA 
column and processed for RNA isolation as per the manufacturer’s instruction. Isolated 
RNA was stored at -80 °C until further used. 
RNA quantification and purity check  
For quantification isolated RNA samples were diluted in DEPC water (2 μl of RNA + 
98 μl of DEPC water, 50 times dilution) and absorbance was measured at two 
wavelengths as 260 nm and 280 nm.  
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 Amount of RNA (μg/μl) = O.D. at 260 nm * 40 * 50 (dilution factor)/ 1000 
 
The ratio of optical densities at 260 nm and 280 nm is an indicator for RNA purity 
(indicative of protein contamination in the RNA samples). Only samples with a ratio of 
1.8 or more were considered to be of acceptable quality.  
RNA integrity check 
Further quality check (if necessary) was performed using a denaturing RNA gel. In 
short 2 % Agarose gel with Ethidium-bromide was casted, RNA samples were mixed 
with RNA loading buffer (4:1 ratio) (Sigma) and were loaded on the gel. 
Electrophoresis was carried out at constant volt (70-100 V) using MOBS running 
buffer for 1 hour and the gel was read on a gel documentation apparatus under UV 
lamp. RNA samples showing a single bright band were considered to be of good 
quality. Loss of RNA integrity could be detected as smear formation in the agarose gel 
(Figure 10). 
 
 
 
 
 
 
 
 Figure 10: Representative agarose gel for RNA integrity check. 
 
cDNA synthesis and real-time RT-PCR 
The RNA samples isolated according to the procedure detailed above were diluted in 
DEPC water to a concentration of 1μg/20μl. A master mix was prepared with reagents 
including 9 μl of 5x buffer (Invitrogen, Karlsruhe, Germany), 1μl of 25mM dNTP 
mixture (Amersham Pharmacia Biotech, Freiburg, Germany), 2 μl of 0.1 M DTT 
(Invitrogen, Karlsruhe, Germany), 1 μl of 40U/μl RNasin (Promega, Mannheim, 
Germany), 0.5μl of 15μg/ml linear acrylamide (Ambion Ltd, Cambridgeshire, UK), 
0.5μl of Hexanucleotide (Roche, Mannheim, Germany), 1μl of Superscript (Invitrogen, 
Karlsruhe, Germany) or ddH2O in case of the controls. The master mix was made to a 
volume of 15μl and added to 2μg/30μl RNA samples were taken in separate DEPC 
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treated microcentrifuge tubes, which were mixed and placed at 42 °C on a thermal 
shaker incubator for 1 hour. After 1 hour the cDNA samples were collected and stored 
at -20 °C until use for real-time RT-PCR analysis.  
The cDNA samples prepared as described above were diluted 1:10 a dilution for the 
real-time RT-PCR. The real-time RT-PCR was performed on a TaqMan® ABI Prism 
7000 or 7700 (Applied Biosystems, Darmstadt, Germany). The quantitative PCR for 
mRNA is based on the employment of sequencespecific primers and likewise 
sequence-specific probes. The latter is tagged at both ends with a fluorescent molecule. 
The quencher absorbs TAMRA (at the 3'-End) the fluorescence of the other reporter 
tagged material such as FAM or VIC at the 5'-End. The TaqMan® universal PCR 
master mix (Applied Biosystems, Darmstadt, Germany) contained Taq polymerase 
possessing a 5' _ 3' polymerase activity and a 5' _ 3 ' exonuclease activity. During the 
elongation phase of the PCR, specifically bound probe was hydrolyzed by the 
exonuclease and the 5'-tag was set free. With every newly synthesized DNA strand 
fluorescent tag material was set free and the resulting fluorescence was measured at 
488nm. The resulting fluorescence signal is directly proportional to the quantity of 
DNA synthesized. The CT value (Cycle Threshold value) was computed for each 
sample. This is the cycle number, with which the reporter fluorescence signal breaks 
through a user-defined threshold. The TaqMan® universal PCR master mix containing, 
the forward primers and Reverse primers (final concentration of 300 nM) and the probe 
(final concentration of 100 NM) was placed on ice. TaqMan® universal PCR master 
mix contained PCR buffers, dNTPs and the AmpliTaqGold® previously mentioned 
(Taq polymerase without 3' _ 5' exonuclease activity). 18μl of the mastermix was 
pipetted into each well of a 96-well plate and 2μl of template (DNA dilution) was 
added to each of these wells. The plate was sealed and centrifuged at 280 xg and 
analyzed using TaqMan® ABI PRISM 7000 or 7700. For the TaqMan® RT-PCR the 
following temperature settings were used: The first incubation was carried out for 2 
minutes at 50°C followed by 95°C for 10 minutes so as to activate the polymerase. 
Templates were amplified during 40 cycles each comprising 15 seconds incubation at 
95°C followed by 1 minute incubation at 60°C. The RT-PCR for the housekeepers (18S 
rRNA or GAPDH) was carried out under similar conditions. The CT values were 
recorded using the ABI PRISM Sequence Detection software (version 1.0) and the 
results were evaluated in relation the respective housekeepers. In all cases controls 
consisting of ddH2O were negative for target and housekeeper genes. Oligonucleotide 
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primer (300 nM) and probes (100 nM) were from Applied Biosystems (Darmstadt, 
Germany): Primers for CCL2, Ccl5, and 18s rRNA was predeveloped TaqMan assay 
reagent from PE Biosystems. 
 
Primers and probes used for real-time RT-PCR 
Target   Sequence 
CCL2   predeveloped TaqMan assay reagent from PE Biosystems 
CCL5    predeveloped TaqMan assay reagent from PE Biosystems 
CCR1    Forward primer: 5'-TTAGCTTCCATGCCTGCCTTATA-3' 
   Reverse primer: 5’-TCCACTGCTTCAGGCTCTTGT-3’ 
   6 FAM: 5’-ACTCACCGTACCTGTAGCCCTCATTTCCC-3’ 
CCR2    Forward primer: 5'-CCTTGGGAATGAGTAACTGTGTGA-3' 
   Reverse primer: 5’-ACAAAGGCATAAAT- 
     GACAGGATTAATG-3’ 
   6 FAM: 5’-TGACAAGCACTTAGACCAGGCCATGCA-3’ 
CCR5    Forward primer: 5'-CAAGACAATCCTGATCGTGCAA-3' 
   Reverse primer: 5’-TCCTACTCCCAAGCTGCATAGAA-3’ 
          6FAM: 5’TCTATACCCGATCCACAGG- 
    AGAACATGAAGTTT-3’ 
TGF-β1   Forward primer: 5'- CACAGTACAGCAAGGTCCTTGC -3' 
   Reverse primer: 5’- AGTAGACGATGGGCAGTGGCT - 3’ 
   6 FAM: 5’ - GCTTCGGCGTCACCGTGCT -3’ 
collagen I-α1   Forward primer: 5'- TGCTTTCTGCCCGGAAGA -3' 
   Reverse primer: 5’- GGGATGCCATCTCGTCCA - 3’ 
   6 FAM: 5’ - CCAGGGTCTCCCTTGGGTCCTACATCT -3’ 
18s rRNA   predeveloped TaqMan assay reagent from PE Biosystems 
 
 
3.2.1.11 FACS analysis 
Total blood and bone marrow samples were obtained from mice of all groups at the end 
of the study for FACS analysis. 
Bone marrow cells isolation 
Tibia and femur bones from the fore and hind limbs of MRLlpr/lpr mice were isolated 
after sacrificing 3 mice from each group, using all sterilized materials and sterile 
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conditions for the isolation in an aseptic hood with HEPA filters. Bones were freed 
from the adhering tissues and both the ends of each bone were punctured with the 24 
gauge needle and then the RPMI media was flushed (using sterile surgical syringe with 
needle) through the bones to isolate bone marrow in a sterile petri plate containing the 
2-3 ml of ice-cold media (RPMI+ 10 %FCS + 1 % PS) on ice. Then it was 
homogenously resuspended using 1 ml pipette. This cell suspension was taken in a 15 
ml Falcon tube using 1 ml pipette and centrifuged at 1600 rpm at 4°C for 6 min. and 
washed with 1x PBS (cell culture grade) for 2 times. Then it was passed through the 40 
μm sterile filters to obtain single cell suspension and centrifuged as before. The 
supernatant was decanted and the pellet was resuspended in 4 ml of sterile 0.3M 
NH4Cl and kept at room temperature for 5 min. Then it was centrifuged as above and 
supernatant was decanted and pellet was resuspended in ice cold (cell culture use) PBS 
and washed 2 times with PBS as before. The pellet was resuspended in RPMI media (1-
2 ml). 
Whole blood collection 
Blood sample was drawn after 2-3 hrs of last injection of Spiegelmer and vehicle in 
respective groups in an ependrof tube containing EDTA. 
Staining bone marrow and blood samples for FACS 
Bone marrow the cells were resuspended to approximately 1-5x106 cells/ml in ice cold 
PBS, 10%FCS, 1% sodium azide. Use ice cold reagents/solutions and at 4oC as low 
temperature and presence of sodium azide prevented the modulation and internalization 
of surface antigens which could produce a loss of fluorescence intensity. 100µl of 
whole blood sample was used for staining. 
1) 100 μl of cell suspension /100µl of whole blood was added to each tube. 
2) 0.1-10 μg/ml of the primary antibody (MC21, Mack et.al 2001) was added. 
Dilutions for primary antibody were made in 3% BSA/PBS. 
3) Incubated for at least 30 min at 4oC in the dark. 
4) Samples were then washed 3-times by centrifugation at 400 g for 5 min and 
resuspend them in ice cold PBS.  
4) Biotinylated anti-rat IgG antibody (BD Biosciences GmbH, Heidelberg, 
Germany) diluted in 3% BSA/PBS at the optimal dilution was added in the samples 
(secondary antibody) and then resuspended the cells in this solution. 
5) Incubated for at least 40 minutes at 4oC in the dark.  
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6) The cells were then washed 3-times by centrifugation at 400 g for 5 min and 
resuspend them in ice cold PBS, 3% BSA, 1% sodium azide. 
7) Then the cells were treated with optimum amount of streptavidin-PE. 
8) Store the samples for 40 min at 4oC in the dark. 
9) The cells were then washed 3-times by centrifugation at 400 g for 5 min and 
resuspend them in ice cold PBS, 3% BSA, 1% sodium azide. 
10) Bone marrow cells were ready for the analysis. Blood samples were then lysed 
with BD lysis buffer (BD Biosciences). Followed by two washings before analysis. 
FACS acquisition 
Stained samples were gated for monocyte region according FSC and SSC plot. Gated 
cells were then plotted against FL2 (for PE fluroscence). 
3.2.1.12 Immunostimulatory effect of Spiegelmer (in vitro) 
 
Isolation and preparation of murine bone marrow derived dendritic cells 
(BMDCs)  
Tibia and femur bones from the fore and hind limbs of MRLlpr/lpr mice were isolated 
after sacrificing 4-5 mice, using all sterilized materials and sterile conditions for the 
isolation in an aseptic hood with HEPA filters. Bones were freed from the adhering 
tissues and both the ends of each bone were punctured with the 24 gauge needle and 
then the RPMI media was flushed (using sterile surgical syringe with needle) through 
the bones to isolate bone marrow in a sterile Petri plate containing the 2-3 ml of ice-
cold media (RPMI+ 10 %FCS + 1 % PS) on ice. Then it was homogenously 
resuspended using 1 ml pipette. This cell suspension was taken in a 15 ml Falcon tube 
using 1 ml pipette and centrifuged at 1600 rpm at 4°C for 6 min. and washed with 1x 
PBS (cell culture grade) for 2 times. Then it was passed through the 40 μm sterile 
filters to obtain single cell suspension and centrifuged as before. The supernatant was 
decanted and the pellet was resuspended in 4 ml of sterile 0.3M NH4Cl and kept at 
room temperature for 5 min. Then it was centrifuged as above and supernatant was 
decanted and pellet was resuspended in ice cold (cell culture use) PBS and washed 2 
times with PBS as before. The pellet was resuspended in RPMI media (2-4 ml) and the 
no. of cells were counted using Neubar’s chamber under the microscope after suitable 
dilution. Adequate no. of cells (5 million) in 12 well plates (NUNC cell culture plates), 
each well containing 1.5 ml of complete RPMI media containing 100 ng/ml 
recombinant murine Flt3 ligand (Immunotools, Friesoyth, Germany). The plates were 
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incubated at 37°C for 8 days to obtain a lineage of mixture of plasmacytoid dendritic 
cells and conventional dendritic cells (pDC and cDC). After 4 days of incubation 1 ml 
of fresh media (with 100 ng/ml Flt3 ligand) was added in each well. After 8 days of the 
incubation, 2 ml of fresh media was replaced for the old media by careful removal only 
from the top of each well. 
Stimulation of BMDCs 
Then the cells were stimulated with ligands or media as followed. 10 μg D- and L-
enantiomeric phosphorothioates RNA40 (TLR7 agonistic sequence), RNA41 and 
RNA42 (control sequences), and various concentrations of mNOX-E36 (12.5, 25 and 
50 μg/mL) and POC-PEG control (25 and 50 mg/mL) in 1,2-dioleoyel-3-trimethyl-
ammonium-propane (DOTAP; Roche, Mannheim, Germany.The plates were again 
incubated for 24 hrs at 37°C. After incubation the supernatants were carefully isolated 
in microcentrifuge tubes. The supernatants were separated from the residual amount of 
cells by centrifuging it at 6000 rpm for 10 min. And immediately stored them at –20°C. 
These supernatants were analyzed for the murine IFN- by (ELISA (PBL, Biomedical 
Labs, and Piscataway, NJ USA) 
3.2.1.13 In-situ hybridization (distribution of mNOX-E36) 
The paraffin-embedded tissue sections were deparaffinised in glass coplin jars at room 
temperature (RT) in used xylene, fresh xylene, used 100% ethanol, fresh 100% ethanol, 
used 95%, 70%, 50% ethanol and phosphate buffered saline (PBS), respectively (1 5 
min each). Sections were fixed again 20 min in 4% (w/v) paraformaldehyde in PBS at 
RT and flushed in PBS. The tissue then was partially digested for 30 min with 20 g/ml 
proteinase K in TE buffer at RT and flushed with 2 mg/ml glycine in PBS at RT and 
PBS, respectively. Pre-hybridisation was carried out in a humidified container for 2 h at 
40°C in pre-hybridisation buffer. Slides were washed once in pre-warmed 2 SSC for 
5 min. The hybridisation with biotinylated L-RNA probes was performed in a 
humidified container overnight with 0.2 M L-RNA probe in pre-hybridisation buffer 
at 40°C.  
The next day slides were washed three times for 15 min (1) with pre-warmed 2 SSC, 
(2) with 2 SSC at RT, and (3) with TBS. Hybridised probes were detected with 
streptavidin alkaline phosphatase 1:1000 in TBS for 2 h at RT. Slides were washed 
again twice for 10 min (1) with TBS and (2) with 10 mM Tris/HCl, pH 9.8; 1 mM 
MgCl2. 5-Bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT) 
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alkaline phosphatase substrate solution (Sigma B1911) was then added and slides were 
incubated for 30-120 min at RT. The reaction was stopped with deionized H2O and 
tissue sections were counterstained with Nuclear Fast Red (Sigma N3020) for 10 min at 
RT. The tissue sections were then dehydrated and embedded in Canada balm or 
Entellan (Merck) for long-term storage. 
3.2.1.14 Statistical analysis  
Statistics were done using GraphPad Prism (4.03 version). Data were expressed as 
mean ± SEM. Data were analysed using unpaired two-tailed t-test for comparison 
between two groups. One-way ANOVA followed by post-hoc Bonferroni`s test was 
used for multiple comparisons. For nonparametric analysis of two groups Two-tailed 
Mann Whitney U test were performed. 
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3.2.2  Methods Part II 
 
3.2.2.1 Grouping and treatment 
Seven week old female MRLlpr/lpr mice were obtained from Harlan Winkelmann 
(Borchen, Germany) and kept in filter top cages under a 12 hour light and dark cycle. 
Water and standard chow (Sniff, Soest, Germany) were available ad libitum. All 
experimental procedures were approved by the local government authorities. At the age 
of 14 week, female MRLlpr/lpr mice were distributed into seven groups that received 
injections as follows: 
 
Table:5  Treatment protocol II 
 
Group Treatment Dosage  level a 
(mg/kg) 
Dose volume
(ml/kg) 
Treatment 
Schedule 
no 
1 Vehicle (5% Glucose) 0 4 3times/week 16 
2 mNOX-E36-PEG 50 4 3times/week 12 
3 revmNOX-E36-PEG  
50 
 
4 
3times/week 16 
4 CYC ¼ th full dose  
30 
 
4 
once/ 4 weeks 16 
5 CYC full dose 30 4 once weekly 12 
6 mNOX-E36-PEG  
plus 
CYC ¼ th full dose 
50 
 
30 
 
4 
3times/week 
 
once/4 weeks 
12 
7 MMF 100 4 once daily 12 
a = in vivo doses of mNOX-E36 and revmNOX-E36-PEG in mg/kg apply to the combined total 
weight of the oligonucleotide part plus the coupled PEG moiety. Thus, mNOX-E36 has to be 
multiplied with the factor 0.29. 
All Spiegelmer samples were provided by Noxxon Pharma AG, in ready to use formulation. 
Cyclophsphamide (CYC) was procured from sigma Aldrich. Mycophenolate mofetil (MMF) 
was purchased from Roche (Manheim, Germany) 
 
 
3.2.2.2 Route and rationale of test material administration 
The chosen route of administration was subcutaneous, as the animals tolerate a large 
number of subcutaneous administrations better than numerous intraperitoneal 
injections, handling is easier and because by this route unPEGylated Spiegelmer is 
present longer in the circulation. So mNOX-E36 and controls were administered 
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subcutaneously (4 mL/kg) three times a week (Monday, Wednesday and Friday), CYC 
intraperitoneally once per month or once weekly and MMF orally at daily intervals. 
3.2.2.3 Test substance and formulation 
Spiegelmer    Sequence 
mNOX-E36-PEG  40 kD PEG 
    5`-GGCGACAUUG GUUGGGCAUG 
    AGGCGAGGCC CUUUGAUGAA 
    UCCGCGGCCA-3` 
Control Spiegelmer  Sequence 
revmNOX-E36-PEG  40 kD PEG 
    5`-ACCGGCGCCUAAGUAGUUUC   
    CCGGAGCGGAGUACGGGUUG    
    GUUACAGCGG-3` 
  
For in vivo application, the mNOX-E36 and the non-functional control Spiegelmer 
were used as modified with 40-kD PEG at the 5` terminus. The test substance 
(Spiegelmer solution) was dissolved in isotonic 5 % glucose solution 
 
3.2.2.4 Pharmacokinetic analysis 
In weeks 1, 3, 7 and 10 of treatment, blood samples for pharmacokinetic analysis were 
collected 24 hours after injection from mNOX-E36 treated groups and determined as 
previously described 
 
3.2.2.5 Plasma, urine and tissue collection 
After 10 weeks of treatment (on the day of sacrifice), blood samples were collected 
under ether anaesthesia 2 to 3 hours after the last administration. Blood was drawn by 
retroorbital bleeding using heparinised capillaries. Plasma was separated by 
centrifugation at 10,000 rpm for 5 minutes. 
Urine samples were collected when the animals were 24 weeks of age. 
At study termination (at the end of the 10-week treatment period), organ weights of 
spleen and lymph nodes were determined. Spleen, lymph nodes, kidney, lung, liver, 
and salivary gland tissue samples were collected from each mouse for histology, RNA 
analysis and Cryo analysis. 
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 3.2.2.6 Biochemical analysis of plasma and urine samples 
Urine albumin (Bethyl Laboratories Inc, Montgomery, TX USA) and creatinine were 
determined using diagnostic kits. Plasma samples were analysed for cytokines (BD 
Pharmingen kits for IL12p40, IL6 and CCL2), TNF- (BioLegend Ltd, San Diego, CA, 
USA) and immunoglobulin (Bethyl Laboratories Inc, Montgomery, USA) using ELISA 
kits.  
 
3.2.2.7 FACS analysis 
Spleen cells were obtained from mice of all groups at the end of the study for FACS 
analysis. 
Isolation and preparation of murine spleen cells 
Spleen was isolated from the MRLlpr/lpr mice after sacrificing it, using all sterilized 
materials and sterile conditions for the isolation in an aseptic hood with HEPA filters. 
Spleen was collected in a sterile petri plate containing 2-3 ml of ice-cold media 
(RPMI+ 10 %FCS + 1 % PS) on ice. Then it was mashed using forceps in the petri 
plate itself and broken into fine pieces of tissues. Then the cell suspension was passed 
through 70 μm plastic filter (BD biosciences) using the 1 ml pipette and collected in 
another sterile plate. This single cell suspension was later collected in a 15 ml Falcon 
tube with pipette and centrifuged at 1600 rpm at 4°C for 6 min. The supernatant was 
decanted and the pellet was resuspended in 4 ml of sterile 0.3M NH4Cl and kept at 
room temperature 5 min. Then it was centrifuged at 1600 rpm at 4°C for 6 min. 
Supernatant was decanted and pellet was resuspended in ice cold (cell culture use) PBS 
and centrifuged at 1600 rpm at 4°C for 6 min.  
Staining of spleen cells for FACS 
Spleen cells were resuspended to approximately 1-5x106 cells/ml in ice cold PBS, 
10%FCS, 1% sodium azide. Use ice cold reagents/solutions and at 4oC as low 
temperature and presence of sodium azide prevented the modulation and internalization 
of surface antigens which could produce a loss of fluorescence intensity.  
1) 100 μl of cell suspension was added to each tube. 
2) 0.1-10 μg/ml of the flurochrome labelled antibody was added. Dilutions for 
primary antibody were made in 3% BSA/PBS. following antibodies were used ; anti-
mouse CD3-FITC, anti-mouse CD45-PE, anti-mouse CD4-APC, anti-mouse CD8-
PerCp and anti-mouse CD25-PerCp (all from BD Pharmingen, Heidelberg, Germany) 
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3) Incubated for at least 45 min at 4oC in the dark. 
4) Samples were then washed 3-times by centrifugation at 400 g for 5 min and 
resuspend them in ice cold PBS.  
5) Store the samples for 40 min at 4oC in the dark. 
 
FACS acquisition 
Stained samples were gated for lymphocytes region according FSC and SSC plot. 
Gated cells were then plotted against FITC (FL1) to identify CD3 positive cells 
population. These cells then gated and plotted in another dot plot (FL3-CD8-PerCp vs 
FL4-CD4.APC) to identify CD3+CD4-CD8- (autoreactive T cells). In other staining 
gated CD3 positive cells were plotted (FL3-CD25-PerCp vs FL4-CD4.APC) to identify 
CD3+CD4+CD25+ (regulatory T cells).Cells number / suspension was determined by 
using Caltag counting beads as per the manufacture’s method. 
3.2.2.8 Statistical analysis 
Statistics were done using GraphPad Prism (4.03 version). Data were expressed as 
mean ± SEM. Data were analysed using unpaired two-tailed t-test for comparison 
between two groups. One-way ANOVA followed by post-hoc Bonferroni`s test was 
used for multiple comparisons. For nonparametric analysis of two groups Two-tailed 
Mann Whitney U test were performed. 
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3.2.3  Methods Part III 
 
3.2.3.1 Grouping and treatment 
Seven week old female MRLlpr/lpr mice were obtained from Harlan Winkelmann 
(Borchen, Germany) and kept in filter top cages under a 12 hour light and dark cycle. 
Water and standard chow (Sniff, Soest, Germany) were available ad libitum. All 
experimental procedures were approved by the local government authorities. At the age 
of 8 week, female MRLlpr/lpr mice were distributed into four groups that received 
injections as follows: 
 
Table: 6 Treatment protocol III 
Group Treatment Dosage  
level a 
(mg/kg) 
Dose 
volume 
(ml/kg) 
Treatment 
Schedule 
no 
1 Vehicle (5% Glucose) 0 4 3 times/week 5 
2 mNOX-E36-PEG 50 4 3 times/week 5 
3 CYC full dose 30 4 once/week 5 
4 mNOX-E36-PEG  
plus 
CYC low 
50 
 
30 
4 3 times/week 
 
once/4 weeks 
5 
      
  
a = in vivo doses of mNOX-E36 in mg/kg apply to the combined total weight of the 
oligonucleotide part plus the coupled PEG moiety. Thus, mNOX-E36 has to be multiplied with 
the factor 0.29. 
All Spiegelmer samples were provided by Noxxon Pharma AG, in ready to use formulation. 
Cyclophsphamide (CYC) was procured from sigma Aldrich.  
 
 
3.2.3.2 Route and rationale of test material administration 
The chosen route of administration was subcutaneous, as the animals tolerate a large 
number of subcutaneous administrations better than numerous intraperitoneal 
injections, handling is easier and because by this route unPEGylated Spiegelmer is 
present longer in the circulation. So mNOX-E36 and controls were administered 
subcutaneously (4 mL/kg) three times a week (Monday, Wednesday and Friday), CYC 
intraperitoneally once per month or once weekly. 
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3.2.3.3 Test substance and formulation 
Spiegelmer    Sequence 
 mNOX-E36-PEG  40 kD PEG 
    5`-GGCGACAUUG GUUGGGCAUG 
    AGGCGAGGCC CUUUGAUGAA 
    UCCGCGGCCA-3` 
            
For in vivo application, the mNOX-E36 was used as modified with 40-kD PEG at the 
5` terminus. The test substance (Spiegelmer solution) was dissolved in isotonic 5 % 
glucose solution 
 
3.2.3.4 Blood samples for FACS 
To evaluate the effect of treatments of blood cell count, blood samples were drawn 
every week. 
 
3.2.3.5 FACS analysis 
Bone Marrow cells, Spleen cells and whole blood samples were obtained from mice of 
all groups at the end of the study for FACS analysis. 
Isolation and preparation of bone marrow cells and murine spleen cells: 
Bone marrow cells were isolated as described in methods part-I. Spleen cells were 
isolated as described in methods part-II 
Staining of procedure for FACS 
Blood samples and Bone marrow samples were stained for monocytes and neutrophills 
by using anti mouse 7/4 –PE and anti mouse Ly6G-FITC antibodies. 
Spleen cells were resuspended to approximately 1-5x106 cells/ml in ice cold PBS, 10% 
FCS, 1% sodium azide. Use ice cold reagents/solutions and at 4oC as low temperature 
and presence of sodium azide prevented the modulation and internalization of surface 
antigens which could produce a loss of fluorescence intensity.  
1) 100 μl of cell suspension was added to each tube. 
2) 0.1-10 μg/ml of the flurochrome labelled antibody was added. Dilutions for 
primary antibody were made in 3% BSA/PBS. following antibodies were used ; anti-
mouse CD3-FITC, anti-mouse CD45-PE, anti-mouse CD4-APC, anti-mouse CD8-
PerCp and anti-mouse CD25-PerCp (all from BD Pharmingen, Heidelberg, Germany) 
3) Incubated for at least 45 min at 4oC in the dark. 
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4) Samples were then washed 3-times by centrifugation at 400 g for 5 min and 
resuspend them in ice cold PBS.  
5) Store the samples for 40 min at 4oC in the dark. 
FACS acquisition 
For bone marrow and Blood samples granulocyte and monocytes region according to 
FSC and SSC plot was gated. Gated cells then plotted (FL2-7/4-PE vs FL1-Ly6G-
FITC). 7/4 bri cells were monocytes and 7/4+Ly6G+ cells were evaluated as neutrophils.   
7/4 med cells were mixed leukocytes (Tsou et al.2007). 
Stained spleen cell samples were gated for lymphocytes region according FSC and SSC 
plot. Gated cells were then plotted against FITC (FL1) to identify CD3 positive cells 
population. These cells then gated and plotted in another dot plot (FL3-CD8-PerCp vs 
FL4-CD4.APC) to identify CD3+CD4-CD8- (autoreactive T cells). In other staining 
gated CD3 positive cells were plotted (FL3-CD25-PerCp vs FL4-CD4.APC) to identify 
CD3+CD4+CD25+ (regulatory T cells) 
Cells number / suspension were determined by using Caltag counting beads as per the 
manufacture’s method. 
3.2.3.6 Colony forming units (CFU-GM) 
To determine the ability of bone marrow cells to form granulocyte colony in culture, 
isolated bone marrow cells were cultured in presence of conditioned media for 
granulocyte growth (methocult media) supplemented with mGM-CSF (10ng/ml) for 12 
days. After ten days, granulocyte colonies were counted using microscopic analysis. 
3.2.3.7 Statistical analysis 
Statistics were done using GraphPad Prism (4.03 version). Data were expressed as 
mean ± SEM. Data were analysed using unpaired two-tailed t-test for comparison 
between two groups. One-way ANOVA followed by post-hoc Bonferroni`s test was 
used for multiple comparisons. For nonparametric analysis of two groups Two-tailed 
Mann Whitney U test were performed. 
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4. Results 
4.1. Results part- I 
 
Lupus nephritis is a chronic renal disease. Loss of self tolerance and impaired clearance 
of autoantigens leads to deposition of immune complexes in renal tissue, which 
initiates the inflammatory cascade. Lupus nephritis is characterised by the induced 
expression of cytokines and chemokines in renal tissue. So far the therapy for lupus 
nephritis is targeted towards modulating immune reaction, but we hypothesised that 
controlling inflammatory cascade in combination with immunomodulators will help to 
reduce the side effects of therapy without compromising its effect. In this study first we 
looked at the efficacy of blocking CCL2 mediated tissue injury in mouse model of 
lupus nephritis (MRLlpr/lpr). We looked at anti-CCL2 Spiegelmer for its 
pharmacokinetics, and pharmacodynamic effects. Results of the first part are 
summarised below. 
 
4.1.1 Pharmacokinetics of the anti-CCL2 Spiegelmer in MRLlpr/lpr mice 
4.1.1.1  Bioavailability 
 
In intervention studies for chronic renal disease determination of plasma levels of 
injected substance is essential as kidney being one of the important excretory organs. In 
order to monitor drug exposure in MRLlpr/lpr mice, Spiegelmer plasma levels were 
determined at weekly intervals. The median plasma levels of mNOX-E36 and mNOX-
E36-3'PEG were approx. 300 nM and 1 µM throughout the study, respectively (Figure 
11). Thus, PEGylation increased the plasma levels of mNOX-E36 and the progressive 
kidney disease of MRLlpr/lpr mice did not modulate the pharmacokinetics of both 
Spiegelmers. In addition, neither drug accumulation nor metabolic induction or 
reduction was obvious.  
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Figure 11: Pharmacokinetics of anti-mCCL2 Spiegelmers in chronic kidney disease. 
Concomitant pharmacokinetic studies were performed for mNOX-E36 and mNOX-E36-PEG in 
female MRLlpr/lpr mice during the course of treatment from 14 to 24 wk of age. Plasma 
sampling was carried out 3 and 24 h after the first weekly injection for the Spiegelmers. 
Spiegelmer plasma levels were determined by modification of a sandwich hybridization 
procedure. 
 
4.1.1.2 Distribution 
Anti-CCL2 Spiegelmer showed an excellent bioavailability profile. Bio-distribution is 
one of the key factors which can predict untoward effects or non specific activity of 
injected drug. To determine distribution of mNOX-E36, tissues were fixed in formalin 
and paraffin-embedded. From these fixed tissues 5 m sections were prepared and 
mounted on silanized glass slides. These sections were then processed to detect 
Spiegelmer by in situ hybridisation. Spiegelmer was found to be distributed mainly in 
tubulointerstitial area of renal tissue (Figure 12). CCL2 has been shown to be expressed 
in this region. Selective binding of the Spiegelmer with its target was seen even 
systemically when we looked at the plasma levels of CCL2 (data shown in later parts of 
the results). This explains the selective binding of mNOX-E36 to murine CCL2 and its 
distribution to high CCL2 expressed area of tissue. 
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Figure 12: Bio distribution of mNOX-E36 in MRLlpr/lpr  mice 
 
4.1.2 Survival rate 
End stage kidney failure is one of the major causes of death in SLE patients. In 
MRLlpr/lpr mice the average median survival time of female mice is around 22 weeks. 
CCL2 antagonist (unPEGylated mNOX-E36 and mNOX-E36) treatment led to 
prolonged median survival time, compared to respective controls. The median survival 
time for mice treated with the vehicle control and POC controls was around 21 – 23 
weeks, and for mice treated with unPEGylated mNOX-E36 (25 mg/kg) it was 26 weeks 
(Figure 13). The PEG form of the drug (50 mg/kg mNOX-E36) was found to be even 
more effective in prolonging survival, with median survival of more than 30 weeks 
(Figure 13). In summary, mNOX-E36 improved the 50 % mortality at the 5 % level of 
statistical significance compared to the vehicle-control MRLlpr/lpr mice. 
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Figure 13: Survival of mice of the various treatment groups was calculated by Kaplan-Meier 
analysis. 
 
4.1.3 Renal parameters 
4.1.3.1  Albumin / creatinine ratio 
Albumin / creatinine ratio is an important clinical parameter for renal disease. In lupus 
nephritis it increases with the progression of kidney inflammation. Treatment with a 
CCL2 antagonist was expected to inhibit progression of renal disease in MRLlpr/lpr mice, 
which can be indicated by the reduction of albumin / creatinine ratio, when compared 
to untreated or POC-treated groups. In week 16 of age, the CCL2 antagonist 
unPEGylated mNOX-E36 at a dose of 25 mg/kg, administered three times per week, 
delayed the onset of renal inflammation, indicated by a statistically significant (p < 
0.05, Figure 14) reduction in proteinuria compared to vehicle control. In week 24 of 
age, there was no significant reduction in the albumin / creatinine ratio, but a definite 
trend indicating protection in all groups treated with mNOX-E36 or unPEGylated 
mNOX-E36 could be seen when compared to the vehicle control (Figure 14). Some of 
the diseased mice from control group died before the final estimation of proteinuria 
might explain, why the protective effect could not reach the significance at week 24. 
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Figure 14: Urine albumin (mg/dl) to creatinine (mg/dl) ratio was measured on week 16, 21 and 
24 of age. Data represented in Mean ± SEM. 
 
 4.1.3.2 Glomerular filtration rate 
Progressing inflammation of the kidneys results in a loss of filtering ability. In 
MRLlpr/lpr mice, the GFR decreases with age. In this study, the GFR was determined by 
the ability of mice to excrete FITC-labelled inulin. Mice treated three times per week 
with mNOX-E36 or unPEGylated mNOX-E36 showed a higher GFR compared to the 
vehicle control or POC-treated group (not statistically significant).  
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Figure 15: Glomerular filtration rate (GFR) was evaluated by determining plasma clearance of 
Inulin-FITC. Plasma concentration of Inulin was measured 5, 10, 15,20,35,60 and 90 min after 
retro-orbital injection. GFR was then calculated using Two phase decay kinetics (Graph Pad 
prism 4.0) 
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4.1.3.3 Renal histology  
 
Female MRLlpr/lpr mice develop and subsequentially die from diffuse proliferative 
immune complex glomerulonephritis, with striking similarities to diffuse proliferative 
lupus nephritis in humans. MRLlpr/lpr mice showed diffuse proliferative 
glomerulonephritis characterised by glomerular macrophage infiltration and a mixed 
periglomerular and interstitial inflammatory cell infiltrate consisting of glomerular and 
interstitial MAC-2 positive macrophages and interstitial CD3-positive lymphocytes. 
 
Activity and chronicity index 
Even at 14 wk of age, MRLlpr/lpr mice revealed proliferative glomerulonephritis with an 
activity index of 4.1 ± 1.1 and a chronicity index of 0.1 ± 0.2. At all dose groups, 
treatment with mNOX-E36 and unPEGylated mNOX-E36 improved the activity and 
chronicity index (Figure 16) of lupus nephritis, markers of renal inflammation. The 
improvement of activity and chronicity index was statistically significant at the 5 % 
level (p = < 0.05, vs. respective POC, Mann Whitney test) after treatment with 50 
mg/kg of mNOX-E36 or 25 mg/kg of unPEGylated mNOX-E36. Administration of 25 
mg/kg of unPEGylated mNOXE36 was less effective on the chronicity index than 
treatment with 50 mg/kg of mNOX-E36 (Figure 16). 
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Figure 16: Renal histopathology in MRLlpr/lpr mice.  Renal sections of 24-wk-old MRLlpr/lpr 
mice were stained with periodic acid-schiff. Disease activity and chronicity was evaluated by 
scoring method established by Austin et.al. 1984 Images are representative for seven to 12 
mice in each group. § p < 0.05 versus respective control Spiegelmer. Magnifications: x100  
 
 
Cellular infiltration 
CD3 positive cells (interstitial) 
Immune cell infiltrates contribute to renal damage in lupus nephritis and CCL2 
mediates the recruitment of T cells and macrophages to MRLlpr/lpr mice (Tesch et al., 
1999). Cellular infiltration is characteristic for glomerulonephritis in MRLlpr/lpr mice. 
Treatment with 50 mg/kg of mNOX-E36 or 25 mg/kg of unPEGylated mNOX-E36 
three times per week reduced CD3 positive cell infiltration significantly (p < 0.01 or < 
0.05, Figure 17) when compared to vehicle control, respectively. 
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Macrophages (interstitial and glomerular) 
 
Macrophages are important inflammatory cells, responsible for tissue destruction. 
Lupus nephritis in MRLlpr/lpr mice leads to significant renal macrophage infiltration. 
Treatment with mNOX-E36 and unPEGylated mNOX-E36 at all dose groups reduced 
the macrophage infiltration (MAC-2 positive cells) in interstitial as well as glomerular 
compartment. This effect was statistically significant for 50 mg/kg of mNOX-E36 (p < 
0.05, interstitial and glomerular, Figure 18) and for 25 mg/kg of unPEGylated mNOX-
E36 (p < 0.05, glomerular, Figure 18) when compared to vehicle control. 
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Figure 17: Renal histopathology in 
MRLlpr/lpr mice.  Renal sections of 24-
wk-old MRLlpr/lpr mice were stained 
with antibodies for CD3 T cells 
(interstitial). Images are representative 
for seven to 12 mice in each group. * 
P< 0.05, ** P<0.01 versus respective 
control Spiegelmer. Magnifications: 
x100 
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Figure 18: Renal histopathology in MRLlpr/lpr mice.  Renal sections of 24-wk-old MRLlpr/lpr 
mice were stained with antibodies for Mac-2 cells (interstitial and glomerular). Images are 
representative for seven to 12 mice in each group. * P< 0.05 versus respective control 
Spiegelmer Magnifications: x400 
 
Morphometry 
 
Tubular atrophy and confluent areas of interstitial fibrosis are associated with advanced 
chronic kidney disease. We used morphometry to quantify these changes and found 
that PEGylated and non-PEGylated anti-CCL2 Spiegelmers reduced interstitial volume, 
tubular cell damage, and tubular dilation, all being markers of the severity and 
prognosis of chronic kidney disease. Compared to vehicle control, the treatment with 
25 mg/kg of unPEGylated mNOX-E36 or 50 mg/kg of mNOX-E36 three times per 
week reduced interstitial fibrosis (p < 0.01), tubular cell damage (p < 0.01) and tubular 
dilation (p < 0.01, Figure 19) 
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Vehicle E36
 
      
IgG deposits 
 
CCL2 plays an important role in chronic inflammation as in lupus nephritis. But it has 
no effect on autoimmune parameters which supports our aim to develop an small 
molecule antagonist which attenuates the inflammation without affatcing the immunity. 
Treatment with mNOX-E36 or unPEGylated mNOX-E36 reduced the cellular 
infiltration and severity of glomerular alterations at the light microscopic level but there 
was no change in extent of IgG depositions in glomeruli of all dose groups (data shown 
in Figure 20). 
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Figure 19: Renal histopathology in 
MRLlpr/lpr mice. Morphometry was 
performed on silver-stained sections 
of mice from all groups as described 
in the concise methods section. The 
interstitial volume index, tubular cell 
damage index, and tubular dilation 
index were calculated as percentage 
of high-power field and are expressed 
as means ± SEM. **P < 0.01, 
***P<0.001 versus respective control 
Spiegelmer 
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Figure 20: Renal histopathology in MRLlpr/lpr mice.  Renal sections of 24-wk-old MRLlpr/lpr 
mice were stained for IgG. Images are representative for seven to 12 mice in each group.  
 
 
4.1.4 Extra-renal autoimmune tissue injury in MRLlpr/lpr mice 
4.1.4.1  Skin lesion 
Cutaneous lupus manifestations, which typically occur in the facial or neck area, were 
less common in mNOX-E36 (50 mg/kg) or unPEGylated mNOX-E36-treated (25 
mg/kg) mice being statistically significant at the 1 % level (p < 0.01, vs. POC-PEG, see 
Figure 21). The percentage of animals with skin lesions was determined to demonstrate 
variability within the group. In control groups, more than 60 % (80 % in 50 mg/kg 
POC-PEG) of the animals showed skin lesions in Week 24. The severity was graded 
from 0 (no lesion), 1 (mild lesion), 2 (moderate) to 3 (severe). The percentage of 
animals with skin lesions was determined to see the variability within the group.  
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 4.1.4.2  Lung histology 
After sacrifice, lung tissue of all mice was prepared and scored semi-quantitatively. 
Treatment with unPEGylated mNOX-E36 and mNOX-E36 at all dose groups reduced 
peribronchiolar inflammation with mean severity grades from 0.42 to 1.2 (controls, 
severity grades from 1.4 to 1.6) in MRLlpr/lpr mice. After the administration of 50 mg/kg 
of mNOX-E36 this effect was statistically significant at the 5 % level when compared 
to the vehicle control (Figure 22). 
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Vehicle E36 Figure 21: Extrarenal autoimmune 
tissue injury in MRLlpr/lpr mice. 
MRLlpr/lpr mice of all groups were 
regularly checked for cutaneous 
lupus manifestations, which typically 
occur at the facial or neck area and 
were less common in anti–mCCL2 
Spiegelmer–treated mice The 
severity was graded from 0 (no 
lesion), 1 (mild lesion), 2 (moderate) 
to 3 (severe).** p< 0.01 vs control 
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Figure 22: Extrarenal autoimmune tissue injury in MRLlpr/lpr mice. At 24 wk of age, lung tissue 
was prepared from MRLlpr/lpr mice of all groups and scored semiquantitatively as described in 
the concise methods section. Treatment with anti-CCL2 Spiegelmers reduced peribronchiolar 
inflammation in MRLlpr/lpr mice. Images are representative of seven to 11 mice in each group. 
Magnification: x100. * p<0.05 vs control group. 
 
4.1.4.3  Splenomegaly and lymphadenopathy 
Female MRLlpr/lpr mice are known to develop a lymphoproliferative syndrome 
characterized by massive splenomegaly and bulks of cervical, axillary, inguinal, and 
mesenterial lymph nodes. Splenomegaly and lymphadenopathy are two of the typical 
morphological clinical signs for lupus in MRLlpr/lpr mice. Treatment with unPEGylated 
mNOX-E36 and mNOX-E36 did not show any effect on spleen (Figure 23) or lymph 
node weights (Figure 23). Thus, treatment with Spiegelmers did not affect 
lymphoproliferation in MRLlpr/lpr mice. 
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   Figure 23: At week 24 of age MRLlpr/lpr mice show massive splenomegaly and 
lymphadenopathy. Data represents organ weight/100 gm body weight of spleen and 
mesenteric lymphnodes of the groups under observation. 
 
 
 
4.1.5 Systemic parameters 
4.1.5.1  Plasma IgGs 
Autoimmunity in MRLlpr/lpr mice is characterised by the production of autoantibodies 
against multiple nuclear antigens including dsDNA. In 24-week old MRLlpr/lpr, plasma 
dsDNA IgG, IgG1, IgG2a, and IgG2b autoantibodies were present at high levels. 
unPEGylated mNOX-E36 and mNOX-E36 both had no effect on either of these DNA 
autoantibodies. Thus, treatment with mNOX-E36 did not affect anti-dsDNA IgG 
production in MRLlpr/lpr mice. 
 
Table 7: Plasma IgG subtypes. 
[μg/ml] Vehicle 
 
mNOX-PoC mNOX-E36 mNOX-PoC-P mNOX-E36-P 
 IgG1 11.7 ± 3.6 7.5 ± 2.8 11.7 ± 3.4 8.2 ± 1.2 6.6 ± 1.2 
IgG2a 2.0 ± 0.3 1.9 ± 0.3 2.1 ± 0.1 2.0 ± 0.2 1.9 ± 0.2 
IgG2b 17.6 ± 5.6 18.9 ± 5.2 22.6 ± 3.3 28.3 ± 2.5 20.6 ± 3.8 
Data presented as Mean ± SEM 
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4.1.5.2  Plasma CCL2 
UnPEGylated mNOX-E36 and mNOX-E36, but none of the control Spiegelmers, were 
found to increase the plasma concentrations of CCL2, indicating that CCL2-specific 
Spiegelmers retain soluble CCL2 in the intravascular compartment. Plasma CCL2 was 
measured in samples collected 3 hours post administration on the day of sacrifice. 
These data showed that pegylation increases the plasma levels of unPEGylated mNOX-
E36, which most effectively retains soluble CCL2 in the intravascular compartment 
(Figure 24). It also explains the selectivity of the treatment for murine CCL2. 
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Figure 24: Plasma CCL2 levels in MRLlpr/lpr mice. Plasma CCL2 levels were determined in 
mice of all groups at the end of the study. Data are expressed as means ± S.E.M.  
 
 
4.1.6 Emigration of monocytes from the bone marrow 
 
Monocyte emigration from bone marrow during bacterial infection was shown to 
involve chemokine receptor CCR2 (Serbina et al.2006), but the role of CCR2 in the 
context of autoimmunity remains hypothetical. To verify the effect of CCL2 blockade 
on monocyte migration with Spiegelmer treatment, we performed a single-dose study of 
the anti-CCL2 Spiegelmer (50 mg/kg), control Spiegelmer (50 mg/kg), and 5% glucose 
(control). 
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Figure 25 : Flow cytometry for CCR2 in peripheral blood and bone marrow of MRLlpr/lpr mice 
(A) To study the effects of anti-CCL2 Spiegelmer on leukocyte evasion from the bone marrow, 
we performed flow cytometry for CCR2 on bone marrow and peripheral blood in 24-wk-old 
vehicle- or anti–CCL2 Spiegelmer–treated MRLlpr/lpr mice. Data are mean percentage of CCR2+ 
cells ± SEM in either bone marrow or peripheral blood in five mice of each group. . (B) Effect 
of single dose of anti-CCL2 Spiegelmer (50 mg/kg), Spiegelmer (Co, 50 mg/kg), and 5% 
glucose on circulating CCR2+ cells. Data are mean percentage of CCR2+F4/80+ cells ± SEM in 
blood 6 h after injection. 
 
 
Anti-CCL2 Spiegelmer significantly reduced the percentage of the circulating CCR2-
positive cells 6 h after injection, compared with the vehicle-treated group. By contrast, 
the control Spiegelmer had no effect (Figure 25B). Furthermore, we examined the 
CCR2-positive monocyte population in peripheral blood and bone marrow in 24-wk-
old MRLlpr/lpr mice that had been treated with anti-CCL2 Spiegelmer or saline from 
weeks 14 to 24 of age. Anti-CCL2 Spiegelmer increased CCR2-positive cells from 13 
to 26% in the bone marrow and reduced this population from 26 to 11% in the 
peripheral blood, respectively (Figure 25A). These data support a novel role for CCL2 
for the evasion of CCR2-positive cells from the bone marrow during autoimmune 
disease of MRLlpr/lpr mice 
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4.1.7 RT-PCR analysis 
In order to study whether treatment with unPEGylated mNOX-E36 and mNOX-E36 
affects intrarenal inflammation in MRLlpr/lpr mice, real-time RT-PCR was performed in 
pooled samples for the proinflammatory chemokines CCL2 and CCL5, which are 
progressively up regulated in kidneys of MRLlpr/lpr mice during progression of renal 
disease. Treatment with Spiegelmers, unPEGylated mNOX-E36 and mNOX-E36, from 
Week 14 to 24 of age reduced renal expression of CCL2 and CCL5 mRNA compared 
to vehicle-treated controls. mRNA levels for CCL2 (Figure 26) and CCL5 (Figure 26) 
were expressed per respective 18s rRNA expression. 
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Figure 26: Renal chemokine 
expression of MRLlpr/lpr mice 
with experimental lupus: Renal 
mRNA expression for the CC-
chemokines CCL2 and CCL5 
was determined by real-time 
reverse transcriptase–PCR using 
total renal RNA pooled from five 
mice of each group. RNA levels 
for each group of mice are 
expressed per respective 18s 
rRNA ex
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4.1.8 Body weight development 
 
After subcutaneous treatment with mNOX-E36 or unPEGylated mNOX-E36, MRLlpr/lpr 
mice gained body weight at all dose groups. In week 24, the mean body weight gains of 
MRLlpr/lpr  mice treated with 16.66 or 50 mg/kg mNOX-E36 and with 8.33, 25 mg/kg or 
25 mg/kg (once weekly) unPEGylated mNOX-E36 were +5 % or −3 % and ±0 %, −1 
% or +6 % higher or lower when compared to the vehicle control . 
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4.1.9 Immunostimulatory effect of Spiegelmer (in vitro) 
 
The therapeutic use of Spiegelmers would be hampered by induction of type 1 
interferon via innate RNA recognition receptors. To exclude this mechanism, 
plasmacytoid dendritic cells (pDC) were prepared from bone marrow of MRLlpr/lpr mice 
and incubated with the anti-CCL2 Spiegelmer and various synthetic RNA. D-
enantiomeric RNA40 but not L-enantiomeric RNA40 induced IFN-  production in pDC 
(Figure 27). Furthermore, IFN-  release was absent upon exposure to control D- and L-
RNA42 as well as high concentrations of the anti-CCL2 Spiegelmer. Hence, 
Spiegelmers do not induce IFN-  production in pDC. In summary, D-RNA-40-P (P-
thioate Backbone) (TLR7 agonist) has shown to induce IFN-α (immunostimulation), 
whereas L-RNA-40-P did not show any induction. mNOX-E36 also did not show 
significant induction of IFN (Figure 27). Hence, this provides a compound as L-
enantiomeric RNA aptamers, without immunostimulatory effect. 
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Figure 27: Spiegelmers do not induce IFN-  release in plasmacytoid dendritic cells. 
Plasmacytoid dendritic cells were generated from bone marrow dendritic cells of MRLlpr/lpr 
mice by incubation with Ftl-3 ligand and incubated with 10 µg each of d- and l-enantiomeric 
phosphorothioates RNA40 (TLR7 agonistic sequence), RNA42 (control sequence) in 1,2-
dioleoyl-3-trimethylammonium-propane (DOTAP), and various concentrations of mNOX-E36. 
IFN-  production was measured by ELISA. Data are means ± SEM of two independent 
experiments 
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4.2 Results Part- II 
 
In the first part of this study we evaluated the efficacy and pharmokinetics of anti-
CCL2 Spiegelmer in MRLlpr/lpr mice. Treatment with mNOX-E36 improved the renal 
phenotype in MRLlpr/lpr mice and had no effect on parameters which defines 
autoimmunity. It was clear that this L-enatiomeric aptamer specifically attenuates 
CCL2-derived inflammation. In the second part of our study we compared the efficacy 
of the anti-CCL2 Spiegelmer with that of known immunomodulators like CYC and 
MMF which are already in clinical use as a therapy for LN. Looking at the 
pathogenesis of lupus nephritis, we assumed that the efficacy will not be comparable, 
but we assumed if we combine the anti-CCL2 Spiegelmer with a low dose of 
cyclophosphamdie, we will be able to reduce the side effects of high exposure of CYC. 
But is the combination therapy as effective as high dose CYC? Results of the second 
part of the study will answer this question. Results are summarised below.  
 
4.2.1 Pharmacokinetics of Spiegelmer in MRLlpr/lpr mice 
 
In order to monitor drug exposure in MRLlpr/lpr mice, mNOX-E36 plasma levels were 
determined in the 1
st
, 3
rd
, 6
th
, and 10
th 
week of treatment, i.e. the 15
th
, 18
th
, 21
st
, and 24
th 
week of age. 24 hours after administration of 50 mg/kg mNOX-E36, median plasma 
levels were approximately 1 μM throughout the study in both of the Spiegelmer-treated 
groups (Figure 28). Apparently, the progressive kidney disease of MRLlpr/lpr mice did 
not modulate Spiegelmer pharmacokinetics and neither drug accumulation nor 
metabolic induction or reduction was detected. 
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Figure 28: Plasma concentration (median) of mNOX-E36 (nM) − MRL lpr/lpr mice 
 
4.2.2 Renal parameters  
4.2.2.1  Renal Histology  
Activity and chronicity index  
At 14 weeks of age MRLlpr/lpr mice showed diffuse proliferative lupus nephritis with an 
activity score index of 4.1 ± 1.1. At this age major abnormalities of the 
tubulointerstitial compartment were absent (data not shown).  
After 10 weeks of treatment, vehicle- and control Spiegelmer-treated MRLlpr/lpr mice 
revealed diffuse proliferative lupus nephritis associated with glomerular 
hypercellularity, expansion of glomerular matrix, focal tuft necrosis, and a mixed 
periglomerular and interstitial inflammatory cell infiltrate (Figure 30). Full dose CYC 
and the combination of mNOX-E36 and ¼ full dose CYC were equally potent in 
improving the activity (Figure 29) and chronicity index (Figure 29) of lupus nephritis, 
markers of renal inflammation. This effect was statistically significant at the 0.1 % 
level (p < 0.001 vs. vehicle control). Furthermore, combination of mNOX-E36 with ¼ 
full dose CYC was significantly (p < 0.05) more effective when compared with ¼ full 
dose CYC treatment alone. ¼ full dose CYC alone, mNOX-E36 alone as well as MMF 
were less potent but still significantly improved the activity (p < 0.05 vs. vehicle 
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control), but only ¼ full dose CYC alone and mNOX-E36 alone improved the 
chronicity indices (p < 0.001 or p < 0.05 vs. vehicle control) of lupus nephritis (Figure 
29). Thus, adding mNOX-E36 to a low dose (30 mg/kg/4 weeks) CYC-based regimen 
is as potent as full dose CYC therapy for diffuse proliferative lupus nephritis in 
MRLlpr/lpr mice. 
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Figure 29: Markers of lupus nephritis in MRLlpr/lpr mice. The activity index (A) and chronicity 
index (B) for DPLN were determined on periodic acid-Schiff-stained renal sections from seven 
to 12 mice from each group as described by Austin et al. (1984) Control Sp, pegylated control 
Spiegelmer (rev-E36-P); anti-CCL2 Sp, pegylated anti-CCL2 Spiegelmer (-E36-P); CYC low, 
monthly 30 mg/kg cyclophosphamide; CYC high, weekly 30 mg/kg cyclophosphamide; MMF, 
100 mg/kg mycophenolate mofetil. *, p < 0.05; **, p < 0.01; ***, p < 0.001 versus vehicle; +, p 
< 0.05 versus CYC low 
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Figure 30: Renal histopathology in MRLlpr/lpr mice. Renal sections of 24-week-old MRLlpr/lpr 
mice from all groups were stained with periodic acid Schiff. Original magnification, x200. 
Control Sp, pegylated control Spiegelmer (rev-E36-P); anti-CCL2 Sp, pegylated anti-CCL2 
Spiegelmer (E36-P); CYC low, monthly 30 mg/kg cyclophosphamide; CYC high, weekly 30 
mg/kg cyclophosphamide; MMF, 100 mg/kg mycophenolate mofetil. Crescentic or globally 
sclerotic glomeruli are indicated by a star, and tubular casts are indicated by an arrow 
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Cellular infiltration  
 
Cellular infiltration is characteristic for glomerulonephritis in MRLlpr/lpr mice. Additive 
effects of an anti-CCL2 Spiegelmer and ¼ full dose CYC combination may relate to 
impaired macrophage and T cell recruitment in MRLlpr/lpr mice. Immunostaining was 
performed for Mac2-positive macrophages and CD3-positive T cells and the number of 
glomerular and interstitial macrophages as well as interstitial T cells was assessed. The 
numbers of glomerular T cells were not analysed as they were very low in all groups.  
 
CD3 positive cells (interstitial)  
 
All treatments reduced CD3 positive cell infiltration significantly (p < 0.001 vs. 
vehicle control, Figure 31), while treatment with full dose CYC or the combination of 
mNOX-E36 and ¼ full dose CYC seemed to be equally potent in reducing the 
numbers of interstitial CD3 positive cell in kidneys of MRLlpr/lpr mice than treatment 
with ¼ full dose CYC alone and mNOX-E36 as well as MMF 
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Figure 31: Renal sections of 24-week-old MRLlpr/lpr mice were stained for CD3-positive T 
cells. Numbers of interstitial T cells were evaluated as mean numbers of CD3-positive cells in 
15 high-power fields (hpf) per section. Data are expressed as means ± S.E.M. Control Sp, 
pegylated control Spiegelmer (rev-E36-P); anti-CCL2 Sp, pegylated anti-CCL2 Spiegelmer 
(E36-P); CYC low, monthly 30 mg/kg cyclophosphamide; CYC high, weekly 30 mg/kg 
cyclophosphamide; MMF, 100 mg/kg mycophenolate mofetil. *, p < 0.05; **, p < 0.01; ***, p 
< 0.001 versus vehicle; ##, p < 0.01 versus CYC low. 
 
 
.  
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Macrophages (glomerular and interstitial)  
 
Full dose CYC and the combination of mNOX-E36 and ¼ full dose CYC were equally 
potent (p < 0.001 vs. vehicle control) in reducing the numbers of glomerular Mac-2 
positive macrophages in kidneys of MRLlpr/lpr mice (Figure 32). Additionally, 
combination of mNOX-E36 with ¼ full dose CYC was significantly more effective in 
reducing the numbers of glomerular Mac2-positive macrophages than treatment with 
¼ full dose CYC alone (p < 0.01). ¼ full dose CYC alone and mNOX-E36 alone as 
well as MMF were less potent but still significantly (p < 0.01 and p < 0.001 vs. vehicle 
control, respectively) reduced the macrophages in glomeruli and the interstitium 
(Figure 32). The number of interstitial Mac2-positive macrophages in kidneys of 
MRLlpr/lpr mice were significantly reduced by full dose CYC and to a lower extend 
equally reduced by ¼ full dose CYC and combination therapy with mNOX-E36 (p < 
0.001 vs. vehicle control, Figure 32). Treatment with mNOX-E36 alone and MMF 
were less potent but still significantly at the 5 % level (p < 0.05 vs. vehicle control). 
Thus, the additive effect of mNOX-E36 and ¼ full dose CYC on renal pathology of 
MRLlpr/lpr mice was associated with a significant reduction of interstitial and 
glomerular macrophages which was similar to the effect of full dose CYC. 
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Figure 32: Renal sections of 24-week-old MRLlpr/lpr mice were stained for Mac-2-positive 
macrophages. The number of glomerular macrophages was evaluated as the mean number of 
Mac2-positive cells in 15 glomeruli (glom.) per section. The numbers of interstitial 
macrophages (D)were evaluated as mean numbers of Mac2-positive cells in 15 high-power 
fields (hpf) per section. Data are expressed as means ± S.E.M. Control Sp, pegylated control 
Spiegelmer (rev-E36-P); anti-CCL2 Sp, pegylated anti-CCL2 Spiegelmer (E36-P); CYC low, 
monthly 30 mg/kg cyclophosphamide; CYC high, weekly 30 mg/kg cyclophosphamide; MMF, 
100 mg/kg mycophenolate mofetil. *, p < 0.05; **, p < 0.01; ***, p < 0.001 versus vehicle; ++, 
p < 0.01 versus CYC low. 
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4.2.3 Extra-renal autoimmune tissue injury in MRLlpr/lpr mice  
4.2.3.1  Lung histology  
Autoimmune peribronchitis is another manifestation of lupus-like systemic 
autoimmunity in MRLlpr/lpr mice. After sacrifice, lung tissue of all mice was prepared 
and scored semiquantitatively. Full dose CYC (30 mg/kg/week) was significantly (p < 
0.001) more effective than ¼ full dose CYC (30 mg/kg/4 weeks) and mNOX-E36 in 
reducing peribronchiolar inflammation in MRLlpr/lpr mice. However, ¼ full dose (30 
mg/kg/4 weeks) CYC plus anti-CCL2 Spiegelmer were as effective as full dose of 
CYC and significantly (p< 0.05) more effective than treatment with mNOX-36 alone 
(Figure 33 and Figure 34). Daily oral treatment with MMF had no effect on lung injury 
in MRLlpr/lpr mice. Thus, the ¼ full dose (monthly) CYC/Spiegelmer combination was 
as effective as full dose (weekly) administrations of 30 mg/kg of CYC on autoimmune 
lung injury in MRLlpr/lpr mice 
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Figure 33: Semiquantitative scoring of lung injury was performed as described Materials and 
Methods. Data represent means ± S.E.M. Control Sp, pegylated control Spiegelmer (rev-E36-
P); anti-CCL2 Sp, pegylated anti-CCL2 Spiegelmer (E36-P); CYC low, monthly 30 mg/kg 
cyclophosphamide; CYC high, weekly 30 mg/kg cyclophosphamide; MMF, 100 mg/kg 
mycophenolate mofetil. * p<0.05,** p<0.01,*** p<0.001 vs vehicle control. 
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CYC (1/4th) + Anti-CCL2 Sp Control Sp 
Anti-CCL2 Sp 
 
 
Figure 34: Autoimmune lung injury in MRLlpr/lpr mice. Lung sections of 24-week-old MRLlpr/lpr 
mice from all groups were stained with periodic acid Schiff. Original magnification, x100. 
Control Sp, pegylated control Spiegelmer (rev-E36-P); anti-CCL2 Sp, pegylated anti-CCL2 
Spiegelmer (E36-P); CYC low, monthly 30 mg/kg cyclophosphamide; CYC high, weekly 30 
mg/kg cyclophosphamide; MMF, 100 mg/kg mycophenolate mofetil. 
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4.2.3.2  Splenomegaly and lymphadenopathy  
 
Splenomegaly and lymphadenopathy are two of the typical morphological clinical 
signs for lupus in MRLlpr/lpr mice. CYC treatment caused a dose-dependent reduction 
of spleen (p < 0.01, full dose CYC) and lymph node (p < 0.001, full and ¼ full dose 
CYC) weights in 24-week old MRLlpr/lpr mice as compared to vehicle-treated MRLlpr/lpr 
mice (Figure 35). The effect of MMF treatment was less evident and did only reduce 
significantly (p < 0.001) weight of lymph nodes. Treatment with mNOX-E36 did not 
show a significant effect on spleen or lymph node weights (Figure 35) and no 
additional effect of mNOX-E36 could be noted when given in combination with ¼ full 
dose of CYC. Thus, mNOX-E36 did not affect lymphoproliferation in MRLlpr/lpr mice 
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Figure 35: Lymphoproliferation in MRLlpr/lpr mice. Spleens and the bulk of mesenteric lymph 
nodes were harvested from 24-week-old MRLlpr/lpr mice. Weight of lymph nodes is expressed 
as mean weight per 100 mg body weight ± S.E.M.  Spleen weights are expressed as mean 
weight per 100 mg body weight ± S.E.M. Control Sp, pegylated control Spiegelmer (rev-E36-
P); anti-CCL2 Sp, pegylated anti-CCL2 Spiegelmer (E36-P); CYC low, monthly 30 mg/kg 
cyclophosphamide; CYC high, weekly 30 mg/kg cyclophosphamide; MMF, 100 mg/kg 
mycophenolate mofetil. *, p < 0.05; **, p < 0.01; ***, p < 0.001 versus vehicle; +, p < 0.05 
versus vehicle (t Test) 
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4.2.4 Plasma cytokines  
4.2.4.1  Plasma IL-12p40 and TNF-α  
Amongst others factors, T cell and monocyte function in autoimmunity and 
antimicrobial host defense is regulated by the two cytokines IL-12 and TNF-α. 
Treatment with mNOX-E36 had no effect on the plasma levels of IL-12p40 or TNF-α. 
By contrast, plasma IL-12p40 and TNF-α levels were markedly (p < 0.001, IL-12p40 
or p < 0.01, TNF-α vs. vehicle control) decreased in MRLlpr/lpr mice treated with full 
dose CYC (Figure 36). ¼ full dose CYC alone and in combination of mNOX-E36 as 
well as MMF alone were less potent but still decreased plasma IL-12p40 (p < 0.05 vs. 
vehicle control). Thus, the anti CCL2 Spiegelmer did not affect plasma cytokine levels 
of IL-12p40 or TNF-α in MRLlpr/lpr mice.  
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Figure 36: Plasma cytokine levels in MRLlpr/lpr mice. Plasma IL-12p40 and TNF-  levels were 
determined by ELISA. Data are means ± S.E.M. from three to 12 mice in each group. Control 
Sp, pegylated control Spiegelmer (rev-E36-P); anti-CCL2 Sp, pegylated anti-CCL2 Spiegelmer 
(E36-P); CYC low, monthly 30 mg/kg cyclophosphamide; CYC high, weekly 30 mg/kg 
cyclophosphamide; MMF, 100 mg/kg mycophenolate mofetil. *, p < 0.05; **, p < 0.01; ***, p 
< 0.001 versus vehicle 
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4.2.4.2  Plasma CCL2 
 
mNOX-E36, but not the control Spiegelmer revmNOX-E36, was found to increase 
statistically significant (p < 0.001 vs. vehicle control) the plasma concentrations of 
CCL2 (Figure 37), indicating that CCL2-specific Spiegelmers retain soluble CCL2 in 
the intravascular compartment. Plasma CCL2 was measured in samples collected 2 to 3 
hours post administration on the day of sacrifice. These data showed that 
pharmacologically relevant levels of circulating mNOX-E36, most likely, binds and 
retains CCL2 in the intravascular compartment. 
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Figure 37: Plasma CCL2 levels in MRLlpr/lpr mice. Plasma CCL2 levels were determined in 
mice of all groups at the end of the study. Data are expressed as means ± S.E.M. Control Sp, 
pegylated control Spiegelmer (rev-E36-P); anti-CCL2 Sp, pegylated anti-CCL2 Spiegelmer 
(E36-P); CYC low, monthly 30 mg/kg cyclophosphamide; CYC high, weekly 30 mg/kg 
cyclophosphamide; MMF, 100 mg/kg mycophenolate mofetil. *** p< 0.001 vs control. 
 
 
4.2.5 Body weight development  
After subcutaneous treatment with mNOX-E36 or revmNOX-E36, MRLlpr/lpr mice 
gained body weight at all dose groups as expected; animals in the groups treated with 
immunosuppressants full dose CYC and MMF lost weight. Mice on ¼ full dose CYC 
and combination therapy showed only minimal or no weight loss at all.  In week 24, the 
mean body weight gains of MRLlpr/lpr mice treated with 50 mg/kg mNOX-E36 were 
(+3.84 g) similar to mean body weight gain in the vehicle group (+5.2 g). In contrast, 
animals in the full dose CYC and MMF showed strong loss of mean body weight (-6.38 
g and -6.52 g, respectively). 
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4.3 Results Part III  
 
We have been able to show that mNOX-E36 treatment improves the renal phenotype in 
MRLlpr/lpr mice. Combining anti CCL2 therapy with low dose CYC shows comparable 
efficacy with that of high dose CYC. But what is the effect of combination therapy on 
overall immunity? is it equally immunosuppressive? or it spares the side effects of  
high dose CYC without hampering the efficacy. To evaluate this, in a separate 
experiment  four satellite groups of MRLlpr/lpr mice were treated for four weeks with 
vehicle, Spiegelmer, Spiegelmer in combination with ¼ full dose CYC, full dose CYC 
alone from 8 to 12 weeks of age in order to characterise immune cell subsets in spleen, 
bone marrow and peripheral blood by flow cytometry (FACS). 
 
4.3.1 Splenomegaly and lymphadenopathy 
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Figure 38:Spleen weights are expressed as mean weight per 100 mg body weight ± S.E.M. 
Spleen cells are expressed as million/spleen. anti-CCL2 Sp, pegylated anti-CCL2 Spiegelmer 
(E36-P-50); CYC(30), weekly 30 mg/kg cyclophosphamide; Combi; mNOX-E36 plus CYC 
(low) *, p < 0.05 versus vehicle;  
 
 
 
Full-dose CYC but not ¼ full dose CYC + mNOX-E36 significantly (p < 0.05 vs. 
vehicle control) reduced the total number of spleen cells and spleen weight. (Figure 
38). This was consistent for all spleen T cell subsets studied, i.e. CD3+, CD3+CD4+ 
CD3+CD8+, CD3+CD4-CD8-, and CD3+CD4+CD25+
 
cells (Figure 39). Thus, 
mNOX-E36 + ¼ full dose CYC had no additive effects on T cell depletion as seen with 
full dose CYC treatment in MRLlpr/lpr mice. 
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Figure 39: T cell depletion in MRLlpr/lpr mice.  Spleens were harvested from 12-week-old 
MRLlpr/lpr mice (n = 5) after 4 weeks of treatment as indicated. Spleen cell suspensions were 
quantified by flow cytometry. CD3-positive T lymphocyte subsets of all the groups are shown. 
Data represent mean percentages ± S.E.M. of all leukocytic cells. anti-CCL2 Sp, pegylated 
anti-CCL2 Spiegelmer (E36-P-50); CYC(30), weekly 30 mg/kg cyclophosphamide; Combi; 
mNOX-E36 plus CYC (low) *, p < 0.05 **,p<0.01 versus vehicle;  
 
 
Full dose of CYC usually causes transient myelosuppression which renders patients 
susceptible to life-threatening infections. Full dose CYC significantly (p < 0.05 vs. 
vehicle control and ¼ full dose CYC + mNOX-E36 combination) reduced the numbers 
of 7/4 (bri) monocytes in bone marrows of MRLlpr/lpr mice while mNOX-E36-treated 
and combined ¼ full dose CYC + mNOX-E36-treated MRL
lpr/lpr 
mice had significantly 
(p < 0.05 vs. vehicle control) elevated numbers of 7/4 (bri) bone marrow monocytes 
(Figure 40). In peripheral blood, test item- and CYC-treated MRLlpr/lpr mice showed a 
trend towards lower 7/4 (bri) monocyte counts but this did not reach statistical 
significance for any of the groups (Figure 40).  
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4.3.2 Effect on blood and bone marrow 
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Figure 40: Myelosuppression in MRLlpr/lpr mice.  Bone marrow and peripheral blood (every 
week) samples were harvested from 12-week-old MRLlpr/lpr mice (n = 5) after 4 weeks of 
treatment as indicated. 7/4high-Positive monocytes were quantified in bone marrows (B) and 
peripheral blood (A) of MRLlpr/lpr mice from all groups Data represent mean percentages ± 
S.E.M. of all leukocytic cells. anti-CCL2 Sp, pegylated anti-CCL2 Spiegelmer (E36-P-50); 
CYC(30), weekly 30 mg/kg cyclophosphamide; Combi; mNOX-E36 plus CYC (low). *, p < 
0.05 **,p<0.01 versus vehicle; +++ p< 0.001 vs combination. 
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4.3.3 CFU-GM colony assay 
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Figure 41: Number of CFU-GM colonies / 3*104  BM cells. Data represented as Mean ± SEM. 
anti-CCL2 Sp, pegylated anti-CCL2 Spiegelmer (E36-P-50); CYC (30), weekly 30 mg/kg 
cyclophosphamide; Combi; mNOX-E36 plus CYC (low). ** p< 0.01 vs control. 
 
 
CFU-GM colony assay in Methocult media supplemented with m-GM-CSF is a test for 
myelosuppression, i.e. the growing capacity of haematopoietic stem cells and immune 
cell progenitors. CFU-GM colonies in full dose CYC-treated mice were significantly 
reduced on day 12 of incubation (p < 0.01 vs. vehicle control and p < 0.05 vs. ¼ full 
dose CYC + mNOX-E36), while mNOX-E36 and ¼ full dose CYC + mNOX-E36 
treatment did not affect CFU-GM counts (Figure 41). Thus, mNOX-E36 + ¼ full dose 
CYC treatment did not cause myelosuppression as seen with full dose CYC in 
MRLlpr/lpr mice. 
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5. Discussion  
 
CCL2 and Lupus nephritis 
Apart from activation of auto-reactive T cells, B cells and production of auto-
antibodies, end stage tissue damage is an important aspect of lupus pathogenesis. 
Tissue inflammation in chronic disease is characterised by hyper infiltration of immune 
cells (T cells, macrophages). Thus targeting molecules (CCL2, CCL5, ICAM, 
integrins) which participate in cell migration would be effective in preventing end stage 
tissue damage. Evidence for a pathogenic role of the CCL2/CCR2 axis in lupus-
associated tissue injury already exists. CCL2- and CCR2-deficient MRLlpr/lpr mice are 
protected from kidney, lung, and skin pathology (Tesch et al. 1999, Perez de Lema et 
al. 2005) Thus, CCL2 and CCR2 both are crucial for the recruitment of cytokine-
producing leukocytes to peripheral tissues. A recent study found that CCR2 is also 
required for the evasion of monocytes from the bone marrow into the intravascular 
compartment during bacterial infection (Serbina NV, Pamer EG. 2006).  
Hasegawa et al (2003) injected 5 x 106 cells that were transfected with an NH2-
truncated CCL2 analogue subcutaneously into 12-wk-old female MRLlpr/lpr mice which 
was associated with an improved pathology at 20 wk. Similar results were obtained by 
Shimizu et al. (2004) who injected 7ND, a NH2-terminal deletion mutant of the CCL2 
gene, into skeletal muscles of 16-wk-old female MRLlpr/lpr mice.In both of the studies 
CCL2 blockade improves the renal pathology without affecting the systemic 
autoimmunity parameters, as none of the above studies showed reduction in 
autoantibodies. This makes CCL2 blockade as attractive approach to attenuate chronic 
inflammation without interfering with immunity.  However, the cell transfer approach 
caused local tumours of considerable size (Hasegawa et al. 2003).The caveat for the use 
of this gene therapy–like approach in humans is that CCL2 antagonism cannot be 
abandoned once initiated.  
 
Spiegelmers: Clinically applicable aptamers 
Cell transfer approach (induction of local tumours) and gene therapy (irreversible 
antagonism) are not clinically applicable in humans. Aptamers can neutralize biologic 
functions of target molecules conceptually similar to antibodies. But aptamers are not 
biostable and can induce immune reaction though recognition by TLRs. Development 
of safer biological aptamers is motivating many groups working all over the globe.  
 91
Spigelmer (L-enantiomeric aptamer) is one of such invention. Unlike aptamers, 
Spiegelmer-based oligonucleotides are nuclease resistant and thus biostable without 
further modifications (Klussmann et al.1996), which makes them very well suited for in 
vivo applications. We evaluated anti-CCL2 Spiegelmer (mNOX-E36), which binds with 
high affinity to murine CCL2 and blocks its function in vitro at low nanomolar 
concentrations. Spiegelmers, being L-enatiomeric, are not recognised by nucleases. 
Because of these structural benefits they remain in systemic circulation for long time 
and have better pharmacokinetics than conventional aptamers. We analysed systemic 
Spiegelmer levels after subcutaneous injection in MRLlpr/lpr mice. Blood samples were 
taken after 3hrs and 24hrs for mNOX-E36 and mNOX-E36-Peg respectively. The 
PEGylated form of mNOX-E36 displayed higher plasma levels compared with the non-
PEGylated mNOX-E36. Levels determined for both form of drugs were sufficient for 
the in vivo application.  Progressive renal failure in MRLlpr/lpr mice did not affect their 
plasma levels.  
We analysed CCL2 levels at termination of the studies at 24 weeks age of MRLlpr/lpr 
mice. Groups treated with anti-CCL2 Spiegelmers (not control Spiegelmers) showed 
higher levels of CCL2. This defines the specificity of Spiegelmer to neutralise murine 
CCL2. Spiegelmers upon interacting with systemic CCL2 neutralises it and keeps it in 
circulation in biologically inactive form. This biological inactivation was seen with 
decreased percentage of CCR2 positive monocytes in peripheral blood. Contrary to 
peripheral blood, percentage of CCR2 positive blood cells in bone marrow was found 
to be elevated in MRLlpr/lpr mice treated with anti-CCL2 Spiegelmer. We looked at the 
in vivo-distribution of mNOX-E36 in MRLlpr/lpr after subcutaneous injection. mNOX-
E36 was seen in tubulointerstitial compartment of renal tissue. CCL2 is known to be 
expressed in high levels in this compartment of renal tissue. All these observations 
show that mNOX-E36 specifically binds to CCL2 and neutralises it in vivo. 
Synthetic oligonucleotides may induce IFN-  in dendritic cells (Heil et al.2004, 
Hornung et al.2005)  through innate pattern recognition receptors in cytosolic or 
endosomal compartments such as Toll-like receptor-7, retinoic acid–inducible protein-
1, or melanoma differentiation–associated gene-5 (Heil et al.2004, Hornung et al.2005) 
IFN-  is an important mediator of autoimmunity (Banchereau J,Pascaul V. 2006) The 
induction of IFN-  would hamper the use of mNOX-36 in lupus nephritis. However, 
Spiegelmers did not induce IFN-  production in dendritic cells, because the L-
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enantiomeric configuration of Spiegelmers is probably not recognized by RNA-specific 
pattern recognition receptors. 
All these properties make anti-CCL2 Spiegelmer (mNOX-E36), a clinically applicable 
apatamer. 
 
Anti-CCL2 Spiegelmer (mNOX-E36) in lupus nephritis 
Our data demonstrate that even non prophylactic late-onset treatment with anti-CCL2 
Spiegelmer at 14 wk of age, a point at which autoimmune tissue injury is already 
established (Tesch et al.1999,Perez de Lema et al.2005), is effective to the same extent 
as CCL2 or CCR2 deficiency, although such knockout animals lack CCL2/CCR2 from 
birth. The consistency of the data from CCL2/CCR2 deficiency and therapeutic CCL2 
blockade may relate to the predominant role of the CCL2/CCR2 axis during the late 
leukocyte recruitment–dependent autoimmune tissue injury rather than the early 
development of autoimmunity in MRLlpr/lpr mice. In fact, both CCL2-deficient and anti-
CCL2 Spiegelmer–treated MRLlpr/lpr mice did not affect the lymphoproliferative 
syndrome, DNA autoantibodies, and renal immune complex deposition, all being early 
disease markers (Tesch et al.1999). Treatment with anti-CCL2 Spiegelmer reduced 
inflammatory cell infiltration in renal tissue, improved renal phenotype, and improved 
survival in MRLlpr/lpr mice. Our findings are consistent with other studies that initiated 
blockade of the CCL2/CCR2 axis after onset of autoimmunity.  
CCL2 blockade is thought to target CCL2-dependent leukocyte adhesion to activated 
endothelia and transendothelial migration of leukocytes at sites of inflammation (Luster 
et al.2005). Our finding that CCL2 blockade has a similar effect on monocyte homing 
to the bone marrow during systemic autoimmunity extends this findings two-fold: First, 
monocyte homing to the bone marrow involves CCL2, possibly acting through CCR2, 
and second, this mechanism seems to apply to systemic inflammation caused by 
infection and autoimmunity.  
 
Current lupus therapy regimen and novel approaches 
The aim of the treatment in lupus nephritis is to suppress the inflammation in renal 
tissue and to preserve the structure and function of the kidney, avoiding the 
progression to renal failure. This objective must be achieved without developing 
significant adverse events. Currently, the therapy for severe lupus nephritis is based on 
the use of high-dose corticosteroids and immunosuppressive drugs. Several 
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randomized controlled studies demonstrated that, for patients with severe lupus 
nephritis, a regimen including CYC is more effective than treatment with only 
glucocorticoids (Steinberg AD et al.1991, Austin HA et al. 1986). Noteworthy, these 
randomized trials of the United States National Institutes of Health (NIH) failed to 
demonstrate significant differences among the different regimens containing 
immunosuppressive drugs (daily oral CYC, monthly intravenous (IV) CYC, daily oral 
azathioprine (AZA), combined low-dose oral CYC plus AZA). Nevertheless, monthly 
IV CYC became the gold standard of treatment for severe lupus nephritis since then. A 
recent study (by Houssiau et al.2002) has showed that, as far as induction of remission 
and prevention of end-stage renal failure is concerned, a 12-week course of IV CYC 
given at a fixed dose of 500 mg fortnightly and followed by AZA for 2 years is as 
effective as an abbreviated NIH protocol consisting on six monthly IV CYC pulses of 
0.5 g/m2 (increasing the dose according to the leukocyte count) followed by two 
quarterly pulses, after a median follow-up of 72 months. Unfortunately, the use of IV 
CYC is not exempt from pitfalls. Despite the treatment with CYC, a significant 
proportion, up to 50%, of patients with lupus nephritis (Korbet SM et al.2000, Ginzler 
EM et al.2005) do not achieve a complete remission. In the studies of the United 
States NIH, a longer duration of the therapy with CYC reduced the cumulative 
probability of relapse, when comparing 24 versus 6 months of treatment (Boumpas DT 
et al.1992), but longer therapy with CYC was associated with increased gonadal 
toxicity. In addition, CYC, even with intravenous administration, has a significant 
toxicity in terms of hemorrhagic cystitis, gonadal failure and infections. 
For the above mentioned reasons, the need for less toxic and more effective 
alternatives to CYC in the treatment of lupus nephritis is clear. 
Because costimulation sustains the abnormal activity of T cells and helps the 
production of autoantibodies, it represents an obvious target in SLE. Thus, several 
approaches aim at decreasing the deleterious effects of T cells by blocking 
costimulation in SLE. CD28/CTLA-4 (Abatacept) and CD80/86, CD40 and CD40 
ligand (L)(BJ9588), ICOS and ICOS-L (anti ICOS antibody) have been targeted to 
normalise activity of T cells. 
Several different B cell targeting strategies have been identified and are currently 
under investigation. These include targets directly associated with the B cell, such as B 
cell surface molecules (CD20, rituxumab) (CD22, Epratuzumab) and more indirect 
targets, such as the inhibition of costimulatory ligands present on the T cell. 
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Figure 42: Mechanisms of current immunotherapies. BCDT: B-cell depletion therapy; Ag: 
antigen; Ab: antibody. Influence of immunotherapeutic drugs indicated by red arrows. Anti-
BLyS acts on BLyS, a B-cell survival factor. Costimulatory molecules CD40 and B7 are 
present on both APC and B-cells. For ease of use, the thicker arrows are only indicated for 
anti-CD40, CTLA4-Ig on APC. 
 
 
All these approaches are meant to target reduced autoantiboby production. None of the 
novel approaches have shown any promising clinical data so far.  
Complexities of the disease prevent us from relying solely on anti-inflammtory 
treatment approach for lupus nephritis.  We hypothesised that blocking inflammatory 
mediators along with low exposure of immunosuppressant like cyclophophamide, can 
improve the renal pathology as effectively as high dose of immunosuppressant. CCL2 
plays an important role in inflammatory phase of lupus. Anti-CCL2 Spiegelmer 
showed good therapeutic benefit in murine model of LN. So we combined anti-CCL2 
Spiegelmer (mNOX-E36) with low dose of cyclophosphamide. This way we thought 
of finding a novel way to reduce immunosuppressant exposure and it also signifies the 
probable role of CCL2 blockade in LN treatment 
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Combining CCL2 blockade with low dose cyclophosphamide 
Immunosuppressive treatment regimen for diffuse proliferative lupus nephritis 
involving high dose CYC or MMF remain associated with serious complications in 
lupus nephritis patients, i.e. infections (Katsifis et al. 2004, Appel et al.2007) Thus, 
combinations of CYC with drugs that more specifically interact with autoimmune 
tissue injury in lupus may overcome this problem. Although the therapeutic effect was 
clearly evident, it remained unclear how the efficacy of the anti-CCL2 Spiegelmer 
would compare with that of CYC or MMF. Based on the specific anti-inflammatory 
mechanism of CCL2 blockade, we assumed that treatment with an anti-CCL2 
Spiegelmer would not be as effective as CYC full dose for the treatment of diffuse 
proliferative lupus nephritis. However, we hypothesized that therapeutic effects 
equivalent to CYC full dose might be achieved with a combination of less frequent 
CYC dosing plus anti-CCL2 Spiegelmer, which may avoid the toxicity of CYC full 
dose. 
It was demonstrated that a combination of mNOX-E36 and monthly (¼ full dose) CYC 
treatment initiated at 14 weeks of age and continued for 10 weeks was as effective as 
weekly (full dose) CYC treatment in suppressing diffuse proliferative lupus nephritis 
and lung injury in MRLlpr/lpr mice. The effect of mNOX-E36 either given alone or in 
combination with a ¼ full dose CYC had no additive effects on T cell depletion, serum 
TNF-α and IL-12p40 levels, and myelosuppression. All these parameters were 
significantly suppressed by full dose CYC therapy. Anti-CCL2 Spiegelmer had no anti-
proliferative effect on immune cells and bone marrow-derived blood cell progenitors as 
the alkylating agent CYC. By contrast, the anti-CCL2 Spiegelmer increased the 
numbers of bone marrow macrophages. As a consequence, mNOX-E36 had no effect 
on the underlying autoimmune dysregulation in MRLlpr/lpr mice. Furthermore, mNOX-
E36 did not modulate the CD4/CD8 double negative ‘autoreactive’ T cell population, 
indicating that mNOX-E36 did not modulate the autoimmune process in itself but 
rather the local mechanisms of autoimmune tissue injury. Additionally, an additive 
effect of combined mNOX-E36 / ¼ full dose CYC therapies on the numbers of renal 
macrophages and T cells was observed which is consistent with the role of CCL2 in 
renal macrophage and T cell recruitment. However, late onset treatment with mNOX-
E36 alone was not as effective as high dose CYC therapy on autoimmune tissue injury 
in MRLlpr/lpr mice. As expected, the non-functional control Spiegelmer was not 
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effective in this lupus nephritis model. The animals tolerated the treatment well and 
there was no influence on body weight development due to Spiegelmer treatment.  
We could see significant renal protection with anti-CCL2 Spiegelmer treatment in 
MRLlpr/lpr mice. But translation of murine efficacy in human clinical efficacy has 
always been a tough task for researchers. Even lupus nephritis phenotype in MRLlpr/lpr 
mice differs with that of human disease. So our data could be encouraging for us but 
may/may not differ interms of efficacy in humans. Anti-CCL2 Spiegelmer (NOX-E36) 
is already in clinical trials for diabetic nephropathy and lupus nephritis as indications. 
Recently phase-I data for pharmacokinetic and pharmacodynamic evaluation has been 
released by NOXXON AG on their website. NOX-E36 in human showed good Pka 
behaviour and could be able to reduce CCR2 positive monocytes in a dose dependent 
manner as pharmcodynamic parameter. It is just a data from healthy individuals from 
phase-I study, data from patients study (phase-II) is still pending.  
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6. Summary and conclusion 
The monocyte chemoattractant protein CCL2 is crucial for monocyte and T cell 
recruitment from the vascular to the extravascular compartment at sites of 
inflammation. CCL2 is expressed in human lupus nephritis and was shown to mediate 
experimental lupus in murine models of lupus nephritis; therefore, CCL2 antagonists 
may be beneficial for therapy. That is why our first aim for this study was to find out 
the efficacy of novel tool i.e. anti-CCL2 Spiegelmer in MRLlpr/lpr mice. This study 
showed the L-enantiomeric RNA oligonucleotide mNOX-E36, an anti-CCL2 
Spiegelmer that binds murine CCL2 with high affinity and neutralizes its action in 
vitro and in vivo. CCL2 antagonism in MRLlpr/lpr mice was shown to be effective 
earlier by some groups using different approaches to block CCL2 e.g. injecting 
transfected cells with mutant CCL2 (Hagesawa et al.2003), gene therapy (Shimizu et 
al.2004), and by using CCL2 knockout mice in MRLlpr/lpr  background (Tesch et 
al.1999). Our experimental approach is more clinically suitable as 1) the mirror image 
configuration of the Spiegelmer confers nuclease resistance and, thus, excellent 
biostability and 2) mNOX-E36 does not induce type I IFN via Toll-like receptor-7 or 
cytosolic RNA receptors, as recently shown for certain synthetic D-RNA.  
Distribution of anti-CCL2 Spiegelmer was confined to the tissue regions where CCL2 
is expressed in MRLlpr/lpr mice. In situ hybridisation located Spiegelmers in the 
tubulointerstitial compartment of the kidney where CCL2 is known to be expressed at 
high levels in these mice. Plasma levels of CCL2 where found to be high in the 
circulation as Spiegelmer tend to bind CCL2 to neutralize it biologically and keep it in 
the circulation. This showed the specificity of anti-CCL2 Spiegelmer for murine CCL2 
in vivo. 
Autoimmune-prone MRLlpr/lpr mice that were treated with a polyethylene glycol form 
of mNOX-E36 from weeks 14 to 24 of age showed prolonged survival associated with 
a robust improvement of lupus nephritis, peribronchial inflammation, and lupus-like 
inflammatory skin lesions. Improvement of lupus nephritis was seen with reduced 
activity index and chronicity index compared to control mice. As anti-CCL2 
Spiegelmer acts by inhibiting the influx of inflammatory cells to injured tissues, we 
found a profound reduction in macrophages and T cell infiltration in renal tissue. But 
at the same time Spiegelmer treatment had no effect of autoimmunity parameters in 
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these mice. Thus, mNOX-E36-based inhibition of CCL2 represents a novel strategy 
for the treatment of lupus nephritis. 
Cyclophosphamide (CYC) can control diffuse proliferative lupus nephritis by potent 
immunosuppression but remains associated with serious and life-threatening 
complications. Drugs that specifically target mediators of diffuse proliferative lupus 
nephritis may help to reduce CYC dose and side effects. In the second part of the study 
we wanted, 1) To compare the efficacy of anti-CCL2 Spiegelmer with that of existing 
therapies for lupus nephitis, 2) To evaluate the efficacy of combining anti-CCL2 
Spiegelmer and low dose of CYC with that of high dose of CYC, 3) To compare the 
safety profile of this combination with high dose CYC.  
To achieve that we injected MRLlpr/lpr  mice with diffuse proliferative lupus nephritis 
from 14 weeks of age with vehicle, weekly 30 mg/kg CYC (full dose), monthly 30 
mg/kg CYC (one-fourth full dose), pegylated control Spiegelmer, pegylated anti-CCL2 
Spiegelmer (3/week), pegylated anti-CCL2 Spiegelmer plus CYC one-fourth full dose 
and mycophenolate mofetil. At week 24, diffuse proliferative lupus nephritis and 
autoimmune lung injury were virtually abolished with CYC full dose but not with 
CYC one-fourth full dose. The CYC one-fourth full dose/Spiegelmer combination was 
equipotent to CYC full dose on kidney and lung injury. Serum IL12p40 and TNF- 
levels were all markedly affected by CYC full dose but not by CYC one-fourth full 
dose.  
In other experimental design with four groups, we injected MRLlpr/lpr mice with 
vehicle, anti-CCL2 Spiegelmer, anti-CCL2 Spiegelmer plus CYC (once/4 weeks) and 
CYC (once/week). We did the treatment for one month before terminating the 
experiment. CYC full dose was associated with reduction in spleen weights, 
CD3+CD4-CD8- T cells and CD3+CD4+CD25+ T cells. No additive effects of anti-
CCL2 Spiegelmer were noted on bone marrow colony-forming unit-granulocyte 
macrophage counts and 7/4(high) monocyte counts, lymphoproliferation, and spleen T 
cell depletion.  
In summary, anti-CCL2 Spiegelmer permits 75% dose reduction of CYC for 
controlling diffuse proliferative lupus nephritis and pneumonitis in MRLlpr/lpr mice, 
sparing suppressive effects of full-dose CYC on myelosuppression and T cell 
depletion. 
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Conclusion 
The Spiegelmer-based inhibition of CCL2/monocyte-chemoattractant protein-1 offers a 
new and promising way to treat lupus nephritis. The compound mNOX-E36 not only 
shows efficacy in MRLlpr/lpr mice but also demonstrates its suitability in terms of 
pharmacokinetic profile as well as its absence of immunostimulatory adverse effects.. 
Furthermore, combination of anti-CCL2 Spiegelmer and CYC therapy permits 
significant dose reduction of CYC and could be proposed as novel strategy to reduce 
CYC toxicity in the treatment of severe lupus.  
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7. Zusammenfassung 
 
CCL2 ist für die Rekrutierung von Monozyten und T-Zellen aus dem Gefäßsystem bei 
Verletzung, Infektion oder Entzündung von wesentlicher Bedeutung. Das Protein ist 
bei Patienten mit Lupusnephritis vermehrt exprimiert und es wurde in früheren Studien 
bereits gezeigt, dass es bei der Entwicklung der Lupusnephritis im Mausmodell eine 
bedeutende Rolle spielt. Demzufolge wurde in dieser Arbeit angenommen, dass CCL2-
Antagonisten neue Therapieoptionen der Lupusnephritis darstellen könnten. Das erste 
Ziel dieser Studie war es daher, die Wirksamkeit des anti-CCL2-Spiegelmers in 
MRLlpr/lpr-Mäusen herauszufinden. Hierfür wurde das L-enantiomere RNA-
Oligonukleotid mNOX-E36, ein anti-CCL2-Spiegelmer verwendet, welches das 
murine CCL2 mit hoher Affinität binden und seine Aktivität sowohl in vitro als auch 
in vivo neutralisieren kann. Die Antagonisierung von CCL2 im MRLlpr/lpr-Mausmodell 
konnte bereits in früheren Studien anderer Arbeitsgruppen als effektive Methode zur 
Behandlung der Lupusnephritis, beispielsweise durch Injektion transfizierter CCL2-
Mutanten (Hagesawa et al.2003), Gentherapie (Shimizu et al.2004) oder durch die 
Verwendung von CCL2-Knockout-Mäusen im MRLlpr/lpr-Hintergrund (Tesch et 
al.1999) nachgewiesen werden. Unser experimenteller Ansatz erweist sich für die 
klinische Anwendung als geeigneter, da zum einen die spiegelbildliche Konfiguration 
der Spiegelmere Nuklease-Resistenz gewährt und daher Spiegelmere eine exzellente 
Biostabilität aufweisen und zum anderen, weil mNOX-E36 keine Typ-I-Interferone via 
Toll-like Rezeptor-7 oder zytosolische RNA-Rezeptoren induziert, wie es kürzlich für 
synthetische D-RNA gezeigt worden ist. 
Die Verteilung des anti-CCL2-Spiegelmers war auf die CCL2-exprimierten Gewebe in 
MRLlpr/lpr-Mäusen begrenzt. Durch in situ-Hybridisierung konnten die Spiegelmere im 
tubulointerstitiellen Kompartment der Niere lokalisiert werden, wo CCL2 
bekanntermaßen vermehrt exprimiert wird. Im Plasma konnten ebenfalls hohe CCL2-
Spiegel nachgewiesen werden, da Spiegelmere dazu tendieren CCL2 zu neutralisieren 
und weiter zirkulieren. Dies zeigte die Spezifität des anti-Spiegelmers für murines 
CCL2 in vivo. 
MRLlpr/lpr-Mäuse, ein murines SLE Modell, wurden mit einer pegylierten Form des 
mNOX-E36 im Alter von 14 bis 24 Wochen behandelt. Diese Mäuse zeigten ein 
verlängertes Überleben, welches mit einer deutlichen Verbesserung der 
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Lupusnephritis, der peribrochialen Entzündung, und der Lupus-ähnlichen 
Hautveränderungen assoziiert war. Die Verbesserung der Lupusnephritis wurde 
anhand des verminderten Aktivitäts- und Chronizitätsindex im Vergleich zur 
Kontrollgruppe bestimmt. Da anti-CCL2-Spiegelmere durch Behinderung des 
Einstroms von Entzündungszellen in verletztes Gewebe wirken, konnten wir eine 
deutliche Reduktion der Makrophagen- und T-Zell-Infiltration im Nierengewebe 
nachweisen. Dennoch hatte die gleiche Spiegelmer-Behandlung keinen Einfluss auf 
Parameter für Autoimmunität in den Mäusen. Somit stellt die mNOX-E36-basierte 
Hemmung von CCL2 eine neue Strategie für die Behandlung der Lupusnephritis dar.  
Cyclophosphamid (CYC) kann die diffuse proliferative Lupusnephrits durch potente 
Immunsuppression kontrollieren. Diese Therapie ist aber mit schwerwiegenden und 
lebensbedrohlichen Komplikationen verbunden. Medikamente, die spezifisch 
Mediatoren der diffusen proliferativen Lupusnephrits erreichen, könnten helfen, die 
CYC-Dosis und damit Nebenwirkungsrate zu reduzieren. Im zweiten Teil dieser 
Studie wollten wir 1) die Wirksamkeit des anti-CCL2-Spiegelmers mit bereits 
existierenden Therapien der Lupusnephritis vergleichen, und 2) die Wirksamkeit des 
anti-CCL2-Spiegelmers in Kombination mit niedrig-dosiertem CYC evaluieren und 3) 
die Nebenwirkungsrate dieser Kombinationsstudie mit der der hoch-dosierten CYC-
Behandlung vergleichen.  
Dazu injizierten wir MRLlpr/lpr-Mäusen mit nachgewiesener diffuser proliferativer 
Lupusnephritis im Alter von 14 Wochen jeweils den Trägerstoff, 30 mg/kg CYC 
wöchentlich (hoch-dosiert), 30 mg/kg CYC monatlich (ein Viertel der hoch-dosierten 
CYC-Gabe), pegyliertes Kontroll-Spiegelmer, pegyliertes Anti-CCL2-Spiegelmer 
(3mal/Woche) sowie pegyliertes Anti-CCL2-Spiegelmer in Kombination mit CYC (ein 
Viertel der hoch-dosierten CYC-Gabe) und Mycophenolat Mofetil. Im Alter von 24 
Wochen war die proliferative Lupusnephritis und die autoimmune Lungenbeteiligung 
durch die Behandlung mit der hoch-dosierten CYC-Gabe komplett aufgehoben, was 
jedoch nicht mit der Behandlung mit niedrig-dosierten CYC (ein Viertel der hoch-
dosierten CYC-Gabe) erreicht werden konnte. Die Behandlung der Kombination aus 
niedrig-dosiertem CYC (ein Viertel der hoch-dosierten CYC-Gabe) und Spiegelmer 
erzielte vergleichbare Ergebnisse bezüglich der Nieren- und Lungenbeteiligung wie die 
die Behandlung mit hoch-dosiertem CYC. IL12p40- und TNF--Werte im Serum 
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waren in der hoch-dosierten CYC-Gruppe deutlich beeinflusst, jedoch nicht in der 
Gruppe mit der niedrig-dosierten CYC-Gabe. 
In einer anderen experimentellen Studie mit vier Gruppen, injizierten wir in MRLlpr/lpr -
Mäusen jeweils den Trägerstoff, anti-CCL2-Spiegelmer, anti-CCL2-Spiegelmer mit 
CYC (1mal/Monat) und CYC (1mal/Woche). Diese Behandlung erfolgte ein Monat. In 
der Gruppe mit der hoch-dosierten CYC-Gabe konnte eine Reduktion des 
Milzgewichts, der CD3+CD4-CD8- T-Zellen und der CD3+CD4+CD25+ T-Zellen 
nachgewiesen werden. Bei der zusätzlichen Gabe von anti-CCL2-Spiegelmer konnte 
kein additiver Effekt in der CFU-GM-positiven Granulozyten- und Makrophagen-
Kolonienzahl und 7/4(high)-positiven Monozyten-Zellzahl im Knochenmark sowie 
Lymphoproliferation und T-Zell-Depletion in der Milz gefunden werden.  
Zusammenfassend ermöglicht die anti-CCL2-Spiegelmer-Therapie eine 75%ige Dosis-
Reduzierung von CYC, um die diffuse proliferative Lupusnephritis und Pneumonitis in 
MRLlpr/lpr-Mäusen zu behandeln, während die suppressiven Eigenschaften der hoch-
dosierten CYC-Gabe mit Knochenmarksuppression und T-Zell-Depletion ausgespart 
werden.  
 
Fazit 
Die Spiegelmer-basierte Hemmung von CCL2 offenbart eine neue und viel-
versprechende Therapieoption für die Behandlung der Lupusnephritis. Das Präparat 
mNOX-E36 zeigt nicht nur Wirksamkeit im MRLlpr/lpr-Mausmodell, sondern 
demonstriert auch seine Eignung im Hinblick auf das pharmakokinetische Profil und 
das Fehlen immunstimulatorischer Nebenwirkungen. Darüber hinaus ermöglicht die 
Kombinationstherapie mit anti-CCL2-Spiegelmer und CYC eine signifikante 
Dosisreduktion von CYC und könnte somit als neue Therapiestrategie zur Toxizitäts-
Reduktion von CYC bei der Behandlung des progressiv verlaufenden Lupus 
vorgeschlagen werden.  
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9. Abbreviations 
 
BM   basement membrane  
BSA   bovine serum albumin 
BUN   blood urea nitrogen 
cDNA   complementary DNA 
CCL2   chemokine C-C motif ligand 2 
CCL5   chemokine C-C motif ligand 5  
CCR1   chemokine C-C motif receptor 1 
CCR2   chemokine C-C motif receptor 2 
CCR3   chemokine C-C motif receptor 3 
CCR5   chemokine C-C motif receptor 5 
CCR7   chemokine C-C motif receptor 7 
CX3CL1  chemokine C-X3-C motif ligand 3  
CXCL10  chemokine C-X-C motif ligand 10  
CXCL12  chemokine C-X-C motif ligand 12 
CXCR2  chemokine C-X-C motif receptor 2 
CXCR4  chemokine C-X-C motif receptor 4 
CXCR7  chemokine C-X-C motif receptor 7 
CX3CR1  chemokine C-X3-C motif receptor 1 
CKD   chronic kidney disease  
CT   cycle threshold 
ddH2O  double distilled water 
DEPC   diethyl pyrocarbonate 
DMEM  Dulbecco’s modified Eagle’s medium 
DMSO  dimethyl sulfoxide 
et al.   et alii = and others 
e.g.   exempli gratia = for instance  
ECM   extracellular matrix 
EDTA   ethylendiamintetra acetic acid 
ELISA   Enzyme-Linked Immunosorbent Assay 
ESRD   end-stage renal disease 
FACS   fluorescence activated cell sorting 
FCS   fetal calf serum 
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FITC   fluorescein isothiocyanate 
GBM   glomerular basement membrane 
GFR   glomerular filtration rate 
HE   Hematoxylin-Eosin 
hpf   high-power-field 
ICAM-1  intercellular adhesion molecule-1 
i.e.   id est = in other words 
IL   interleukin 
IFN-   interferon- 
kDa   kilo Dalton 
MCP   monocyte chemoattractant protein  
MCP-1  monocyte chemoattractant protein-1 
MCP-2  monocyte chemoattractant protein-2 
min   minute/minutes 
ml/min  milliliter/minute 
M/M   monocytes / macrophages 
mNOX-E36  anti-CCL2 Spiegelmer  
mRNA   messenger ribonucleic acid 
n.d.   nondeteclable 
NF-B   nuclear factor-B 
O.D.   optical density 
PAS   Periodic acid Schiff  
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
pDCs   plasma dendritic cells  
POC   scrambled sequence of RNA  
   (Control Spiegelmer for mNOX-E36) 
RANTES  regulated on activation normal T cell expressed and secreted  
RNA   ribonucleic acid 
Rnase   ribonuclease 
RPM   revolutions per minute 
RPMI Medium cell culture medium  
rRNA   ribosomal ribonucleic acid 
RT   room temperature 
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RT-PCR  real-time reverse transcription-polymerase chain reaction 
s    second 
TGF-   transforming growth factor- 
Th1   T helper cell type 1 
TNF-   tumor necrosis factor- 
U   units 
VCAM-1  vascular cell adhesion molecule-1 
VEGF   vascular endothelial growth factor 
vs   versus 
v/v   volume/volume 
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Appendix 
 
1. FACS buffer :  
 Sterile DPBS   500 ml 
 Na Azide  500 mg (0.1 % ) 
 BSA   1 g (0.2 %) 
2. Paris Buffer: 
20 mM Tris-HCL, 125 mM NaCl,  10 mM KCl, 10 mM Sodium acetate, 
5 mM Glucose. 
For 1000 ml: 
Tris-HCL (MW 121.14)  2.4228 g 
NaCl (MW 58.44)   7.31 g 
KCl (MW 74.56)   0.74556 g 
Sod. Acetate (MW 82.03)  0.8203 g 
D-Glucose (MW 180.16)  0.9 g 
 
3. 10X HBSS (Hank’s Balanced Saline Solution) with Ca, Mg: 
  For 1000 ml 
  KCl   4 g 
KH2PO4  0.6 g 
NaCl   80 g 
Na2HPO4.2H2O 0.621 g 
NaHCO3  3.5 g 
CaCl2    1.4 g (or CaCl2.2H2O 1.854 g) 
MgCl2.6H2O  1 g 
MgSO4.7H2O  1 g 
D-Glucose  10 g 
  Dissolve in 900 ml of distilled water and adjust to pH 7.4 with 1N HCl 
  or 1N  NaOH. Make up the volume with distilled water to 1000 ml. 
 
4. 10X HBSS (Hank’s Balanced Saline Solution) without Ca, Mg: 
  For 1000 ml 
  KCl   4 g 
  KH2PO4  0.6 g 
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  NaCl   80 g 
  Na2HPO4.2H2O 0.621 g 
  Dissolve in 1000 ml and autoclave. 
 
5. DNAse stock solution (1 mg/ml): 
  DNAse (type III) 15000 U/6 mg (Sigma D5025) 
 To prepared 1 mg/ml solution: Add 6 ml of 50 % (w/v) Glycerol in 20 
 mM Tris-HCl (pH 7.5), 1 mM MgCl2.  
  Can be kept at – 20 0C for several weeks. 
  Caution: Solution is stable only for 1 week at 4 0C. 
 
6. 50 % Glycerol in 20 mM Tris-HCl (pH 7.5), 1 mM MgCl2: 
  a. 0.48 g of Tris-HCl in 100 ml of distilled water, adjust pH to 7.4 (= 40 
  mM)  
  b. 50 ml of Glycerol 100 % + 50 ml of 40 mM Tris-HCl (20 mM) 
  c. Add 100 ul of 1M MgCl2 solution. 
 
7. Collagenase / DNAse solution: 
  1 mg/ml Collagenase, 0.1 mg/ml DNAse in 1X HBSS (with Ca, Mg) 
 For 10 ml: 
 Collagenase (type I) (Sigma C0130)  10 mg 
 1 mg/ml DNAse stock solution  1 ml 
 HBSS (with Ca, Mg)    9 ml 
  To be preheated in 37 0C water bath before use. 
  Caution: Prepare freshly every time (Stable only for few days) 
 
8. Collagenase solution: 
  1 mg/ml Collagenase in 1X HBSS (with Ca, Mg)  
  For 10 ml: 
  Collagenase (type I)   10 mg 
  HBSS (with Ca, Mg)    10 ml 
  To be preheated in 37 0C water bath before use. 
  Caution: Prepare freshly every time (Stable only for few days) 
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 9. EDTA 2 mM: 
 EDTA 7.44 mg in 10 ml HBSS (without Ca, Mg) 
 To be preheated in 37 0C water bath before use. 
 
9. MACS Buffer 
 PBS pH 7.2 
 0.5% bovine serum albumin 
 2 mM EDTA 
  
10. Citrate buffer 10X 
 110 mM Sodiumcitrate 
 in ddH2O  
 with 2N NaOH to pH 6  
 
11. PBS 
 2.74 M NaCl 
 54 mM KCl 
 30 mM KH2PO4 
 130 mM Na2HPO4 
 in ddH2O  
 Adjust pH to 7.5  with HCl 
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